0001213900-21-042941.txt : 20210816 0001213900-21-042941.hdr.sgml : 20210816 20210816160140 ACCESSION NUMBER: 0001213900-21-042941 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 47 CONFORMED PERIOD OF REPORT: 20210630 FILED AS OF DATE: 20210816 DATE AS OF CHANGE: 20210816 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Viveon Health Acquisition Corp. CENTRAL INDEX KEY: 0001823857 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39827 FILM NUMBER: 211177692 BUSINESS ADDRESS: STREET 1: C/O GIBSON, DEAL, AND FLETCHER, P. C. STREET 2: 3953 CITY: NORCROSS STATE: GA ZIP: 30092 BUSINESS PHONE: 4045797978 MAIL ADDRESS: STREET 1: C/O GIBSON, DEAL, AND FLETCHER, P. C. STREET 2: 3953 CITY: NORCROSS STATE: GA ZIP: 30092 10-Q 1 f10q0621_viveonhealthacq.htm QUARTERLY REPORT

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

  

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2021

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                  to

 

Commission File No. 001-39827

 

VIVEON HEALTH ACQUISITION CORP.
(Exact name of registrant as specified in its charter)

 

Delaware   85-2788202
(State or other jurisdiction of
incorporation or organization)		   (I.R.S. Employer
Identification No.) 

 

c/o Gibson, Deal & Fletcher, PC
Spalding Exchange
3953 Holcomb Bridge Road
Suite 200
Norcross Georgia 30092
(Address of Principal Executive Offices, including zip code)

 

(404)-861-5393
(Registrant’s telephone number, including area code)

 

N/A
(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   VHAQ   NYSE American, LLC
Warrants   VHAQW   NYSE American, LLC
Units   VHAQ   NYSE American, LLC
Rights   VHAQR   NYSE American, LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

☐ Large accelerated filer ☐ Accelerated filer
☒ Non-accelerated filer ☒ Smaller reporting company
  ☒ Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes ☒ No ☐

 

As of August 16, 2021, there were 25,156,250 shares of the Company’s common stock, $0.0001 par value per share, issued and outstanding.

 

 

 

 

 

 

TABLE OF CONTENTS

 

    Page
     
PART 1 – FINANCIAL INFORMATION  
     
Item 1. FINANCIAL STATEMENTS (Unaudited) 1
     
  Condensed Balance Sheets 1
     
  Condensed Statements of Operations 2
     
  Condensed Statements of Changes in Stockholders’ Equity 3
     
  Condensed Statement of Cash Flows 4
     
  Notes to Condensed Financial Statements 5
     
Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 15
     
Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 18
     
Item 4. CONTROLS AND PROCEDURES 18
     
PART II – OTHER INFORMATION  
Item 1 LEGAL PROCEEDINGS 19
Item 1A RISK FACTORS 19
Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 19
Item 3 DEFAULTS UPON SENIOR SECURITIES 19
Item 4 MINE SAFETY DISCLOSURES 19
Item 5 OTHER INFORMATION 19
Item 6. EXHIBITS 20
     
SIGNATURES 21

 

i

 

 

PART 1 – FINANCIAL INFORMATION

 

Item 1. FINANCIAL STATEMENTS

VIVEON HEALTH ACQUISITION CORP.
CONDENSED BALANCE SHEETS

 

   June 30,
2021		   December 31,
2020		 
   (unaudited)     
Assets:        
Cash and cash equivalents  $1,056,622   $3,096,956 
Prepaid Expenses   339,671    660,695 
Total current assets   1,396,293    3,757,651 
Investment held in Trust Account   203,272,741    203,262,660 
Total Assets  $204,669,034   $207,020,311 
           
Liabilities and Stockholders’ Equity          
Current liabilities          
Accrued costs and expenses  $75,767   $958,292 
Other payable – related party   
—
    364,880 
Promissory note – related party   
—
    228,758 
Due to related party   115,806    5,806 
Total current liabilities   191,573    1,557,736 
Deferred underwriting fee   7,043,750    7,043,750 
Warrant liability   6,631,815    10,763,361 
Total liabilities   13,867,138    19,364,847 
           
Commitments and Contingencies   
 
    
 
 
           
Common Stock subject to possible redemption, 18,396,227 and 18,084,699 shares at redemption value at June 30, 2021 and December 31, 2020, respectively   185,801,895    182,655,456 
           
Stockholders’ Equity:          
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding   
—
    
—
 
Common stock, $0.0001 par value; 60,000,000 shares authorized; 6,760,023 and
7,071,551 shares issued and outstanding (excluding 18,396,227 and 18,084,699 shares subject to possible redemption) at June 30, 2021 and December 31, 2020, respectively		   676    707 
Additional paid-in capital   3,641,297    6,813,454 
Retained Earnings (Accumulated deficit)   1,358,028    (1,814,153)
Total stockholders’ Equity   5,000,001    5,000,008 
Total Liabilities and Stockholders’ Equity  $204,669,034   $207,020,311 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

1

 

 

VIVEON HEALTH ACQUISITION CORP.

CONDENSED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

   Three months
ended
June 30,
2021		   Six months ended
June 30,
2021		 
Formation and operating costs  $648,124   $969,557 
Loss from Operations   (648,124)   (969,557)
           
Other income:          
Interest earned on investments held in Trust Account    5,069    10,081 
Interest earned on bank account   30    111 
Change in fair value of warrant liability   233,873    4,131,546 
Total other income   238,972    4,141,738 
           
Net (loss) income  $(409,152)  $3,172,181 
           
Basic and diluted, weighted average shares outstanding – non-redeemable common stock   6,719,958    6,892,838 
Basic and diluted net (loss) income per share  $(0.06)  $0.46 
Basic and diluted weighted average shares outstanding – redeemable common stock   18,436,292    18,263,412 
Basic and diluted net income per share  $0.00    0.00 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

2

 

  

VIVEON HEALTH ACQUISITION CORP.

CONDENSED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY

(UNAUDITED)

  

FOR THE SIX MONTHS ENDED JUNE 30, 2021

 

           Additional   Retained Earnings/   Total 
   Common Stock   Paid-in   (Accumulated   Stockholders’ 
   Shares   Amount   Capital   Deficit)   Equity 
Balance as of January 1, 2021   7,071,551   $707   $6,813,454   $(1,814,153)  $5,000,008 
Deferred offering costs   —    
—
    (25,749)   
—
    (25,749)
Net income   —    
—
    
—
    3,172,181    3,172,181 
Change in common stock subject to possible redemption   (311,528)   (31)   (3,146,408)   
—
    (3,146,439)
Balance as of June 30, 2021   6,760,023   $676   $3,641,297   $1,358,028   $5,000,001 

 

FOR THE THREE MONTHS ENDED JUNE 30, 2021

 

           Additional   Retained Earnings/   Total 
   Common Stock   Paid-in   (Accumulated   Stockholders’ 
   Shares   Amount   Capital   Deficit)   Equity 
Balance as of March 31, 2021   6,719,513   $672   $3,232,152   $1,767,180   $5,000,004 
Net loss   —    
—
    
—
    (409,152)   (409,152)
Change in common stock subject to possible redemption   40,510    4    409,145    
—
    409,149 
Balance as of June 30, 2021   6,760,023   $676   $3,641,297   $1,358,028   $5,000,001 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

3

 

  

VIVEON HEALTH ACQUISITION CORP.

CONDENSED STATEMENT OF CASH FLOWS

SIX MONTHS ENDED JUNE 30, 2021
(UNAUDITED)

 

Cash flows from operating activities:    
Net Income  $3,172,181 
Adjustments to reconcile net income to net cash used in operating activities:     
Interest earned on investments held in Trust Account   (10,081)
Change in fair value of warrant liability   (4,131,546)
Changes in operating assets and liabilities:     
Prepaid assets   321,024 
Accrued costs and expenses   (908,274)
Due to related party   110,000 
Net cash used in operating activities   (1,446,696)
      
Cash Flows from Financing Activities:     
Payment of promissory note   (228,758)
Payment of other payable – related party   (364,880)
Net cash used in financing activities   (593,638)
      
Net change in cash and cash equivalents   (2,040,334)
Cash and cash equivalents, beginning of period   3,096,956 
Cash and cash equivalents, end of the period  $1,056,622 
      
Supplemental disclosure of cash flow information:     
Change in value of common stock subject to possible redemption  $3,146,439 
      

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

4

 

 

VIVEON HEALTH ACQUISITION CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2021

(Unaudited)

 

Note 1 — Organization and Business Operations

 

Viveon Health Acquisition Corp. (the “Company”) is a newly organized blank check company incorporated as a Delaware company on August 7, 2020. The Company was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities (“Business Combination”).

 

We have neither engaged in any operations nor generated any revenues to date. Our only activities from August 7, 2020 (inception) through June 30, 2021 were organizational activities, those necessary to prepare for the Initial Public Offering, described below, and, after our Initial Public Offering, identifying a target company for a Business Combination. We do not expect to generate any operating revenues until after the completion of our Business Combination. We generate non-operating income in the form of interest income on marketable securities held after the Initial Public Offering. We incur expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses. The Company’s sponsor is Viveon Health LLC, a Delaware limited liability company (the “Sponsor”).

 

Upon closing of the IPO and the sale of the Over-Allotment Units, $203,262,500 (approximately $10.10 per Unit) from net offering proceeds of the sale of the Units in the IPO and the sale of the Private Warrants was placed in a trust account (the “Trust Account”) and invested in U.S. government securities, with a maturity of 180 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act, which invest only in direct U.S. government treasury obligations. Except with respect to interest earned on the funds held in the Trust Account that may be released to the Company to pay its tax obligations, the proceeds from the IPO will not be released from the Trust Account until the earliest to occur of (1) the completion of the Company’s initial Business Combination within 15 months and (2) the Company’s redemption of 100% of the outstanding public shares if the Company has not completed a business combination in the required time period.

 

The Company’s management has broad discretion with respect to the specific application of the net proceeds of the IPO, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the assets held in the Trust Account (as defined below) (net of amounts disbursed to management for working capital purposes, if permitted, and excluding the amount of any deferred underwriting commissions) at the time of the agreement to enter into the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires an interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act 1940, as amended (the “Investment Company Act”).

 

In connection with any proposed initial Business Combination, the Company will either (1) seek stockholder approval of such initial Business Combination at a meeting called for such purpose at which public stockholders may seek to convert their public shares, regardless of whether they vote for or against the proposed business combination, into their pro rata share of the aggregate amount then on deposit in the trust account (net of taxes payable) or (2) provide its public stockholders with the opportunity to sell their public shares to the Company by means of a tender offer (and thereby avoid the need for a stockholder vote) for an amount equal to their pro rata share of the aggregate amount then on deposit in the trust account (net of taxes payable), in each case subject to the limitations described herein.

  

If the Company determines to engage in a tender offer, such tender offer will be structured so that each public stockholder may tender any or all of his, her or its public shares rather than some pro rata portion of his, her or its shares. If enough stockholders tender their shares so that the Company is unable to satisfy any applicable closing condition set forth in the definitive agreement related to its initial Business Combination, or the Company is unable to maintain net tangible assets of at least $5,000,001, the Company will not consummate such initial Business Combination. The decision as to whether it will seek stockholder approval of a proposed business combination or will allow stockholders to sell their shares to the Company in a tender offer will be made by the Company based on a variety of factors such as the timing of the transaction or whether the terms of the transaction would otherwise require us to seek stockholder approval.

 

If the Company provides stockholders with the opportunity to sell their shares to it by means of a tender offer, it will file tender offer documents with the SEC which will contain substantially the same financial and other information about the initial Business Combination as is required under the SEC’s proxy rules. If the Company seeks stockholder approval of its initial Business Combination, the Company will consummate the business combination only if a majority of the outstanding shares of common stock present in person or by proxy at a meeting of the Company are voted in favor of the business combination.

 

5

 

 

Notwithstanding the foregoing redemption rights, if the Company seeks stockholder approval of its initial Business Combination and the Company does not conduct redemptions in connection with its initial Business Combination pursuant to the tender offer rules, the Amended and Restated Certificate of Incorporation will provide that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Exchange Act), will be restricted from redeeming its shares with respect to more than an aggregate of 20% of the shares sold in this offering, without the Company’s prior consent. The Company’s sponsor, officers and directors (the “initial stockholders”) have agreed not to propose any amendment to the Amended and Restated Certificate of Incorporation (a) that would modify the substance or timing of the Company’s obligation to provide for the redemption of its public shares in connection with an initial Business Combination or to redeem 100% of its public shares if the Company does not complete its initial Business Combination within 15 months from the closing of the IPO (the “Combination Period”) or (b) with respect to any other material provisions relating to stockholders’ rights or pre-initial Business Combination activity, unless the Company provide its public stockholders with the opportunity to redeem their shares of common stock in conjunction with any such amendment.

 

If the Company is unable to complete its initial Business Combination within the Combination Period, the Company will: (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than five business days thereafter, redeem 100% of the outstanding public shares (including any public units in this offering or any public units or shares that its initial stockholders or their affiliates purchased in this offering or later acquired in the open market or in private transactions), which will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably practicable following such redemption, subject to the approval of the Company’s remaining holders of common stock and its board of directors, proceed to commence a voluntary liquidation and thereby a formal dissolution of the Company, subject (in the case of (ii) and (iii) above) to its obligations to provide for claims of creditors and the requirements of applicable law.

 

The Company’s initial stockholders agreed to waive their rights to liquidating distributions from the Trust Account with respect to any founder shares held by them if the Company fails to complete its initial Business Combination within the Combination Period. However, if the initial stockholders acquire public shares in or after the IPO, they will be entitled to liquidating distributions from the Trust Account with respect to such public shares if the Company fails.

 

Risks and Uncertainties 

 

Management is currently continuing to evaluate the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Liquidity and Capital Resources

 

As of June 30, 2021, the Company had $1,056,622 of cash and cash equivalents held outside the Trust Account available for working capital needs. All remaining cash held in the Trust Account is generally unavailable for the Company’s use, prior to an initial business combination, and is restricted for use either in a Business Combination or to redeem common stock. As of June 30, 2021 and December 31, 2020, none of the amount in the Trust Account was available to be withdrawn as described above.

  

The Company anticipates that the $1,056,622 outside of the Trust Account as of June 30, 2021, will be sufficient to allow the Company to operate for at least the next 12 months from the issuance of the financial statements, assuming that a Business Combination is not consummated during that time. Until consummation of its Business Combination, the Company will be using the funds not held in the Trust Account, and any additional Working Capital Loans (as defined in Note 5) from the initial stockholders, the Company’s officers and directors, or their respective affiliates (which is described in Note 5), for identifying and evaluating prospective acquisition candidates, performing business due diligence on prospective target businesses, traveling to and from the offices, plants or similar locations of prospective target businesses, reviewing corporate documents and material agreements of prospective target businesses, selecting the target business to acquire and structuring, negotiating and consummating the Business Combination.

 

6

 

 

Emerging Growth Company

 

The Company is an “emerging growth company”, as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

 

In addition, Section 107 of the JOBS Act also provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company intends to take advantage of the benefits of this extended transition period.

 

Note 2 — Significant Accounting Policies

 

Basis of Presentation 

 

The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented.

  

The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K/A for the year ended December 31, 2020 as filed with the SEC on July 2, 2021, which contains the audited financial statements and notes thereto. The interim results for the six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any future interim periods.

 

Use of Estimates

 

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The cash equivalents in the amount of $950,419 and $3,092,771, were held in money market funds as of June 30, 2021 and December 31, 2020, respectively.

 

Marketable Securities Held in Trust Account

 

At June 30, 2021 and December 31, 2020, substantially all of the assets held in the Trust Account were held in mutual funds which invest in U.S. Treasury securities. The mutual fund assets in the amount of $203,272,741 and $203,262,660 were held in the Trust Account as of June 30, 2021 and December 31, 2020, respectively.

 

Warrants

 

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date for Private Warrants while the warrants are outstanding.

 

7

 

 

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance and recorded as a warrant liability. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations.

 

Common Stock Subject to Possible Redemption

 

The Company accounts for its common stock subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Common stock subject to mandatory redemption (if any) is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock feature certain redemption right that is considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet. At June 30, 2021 and December 31, 2020, 18,396,227 and 18,084,699 shares of common stock subject to possible redemption are presented as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet.

 

Income Taxes 

 

The Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, “Income Taxes” (“ASC 740”). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

 

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of June 30, 2021. The Company’s management determined that the United States is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties for the three-month period ending June 30, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.

 

Net Income Per Common Share

 

Net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. The calculation of diluted loss per common share does not consider the effect of the warrants issued in connection with the (i) IPO, (ii) exercise of over-allotment and (iii) Private Placement since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. The warrants are exercisable to purchase 19,062,500 shares of common stock in the aggregate.

 

The Company’s statement of operations includes a presentation of net income per share for common stock subject to possible redemption in a manner similar to the two-class method. Net income per common share, basic and diluted, for redeemable Common Stock is calculated by dividing the interest income earned on the Trust Account, net of applicable franchise and income taxes, by the weighted average number of redeemable common stock outstanding since original issuance.

 

8

 

 

Reconciliation of Net Income per Common Share

 

Net income per common share, basic and diluted, for redeemable common stock is calculated by dividing the interest income earned on the Trust Account, by the weighted average number of redeemable common stock outstanding since original issuance. Net income per common stock, basic and diluted, for non-redeemable Common Stock is calculated by dividing the net income, adjusted for income attributable to redeemable common stock, by the weighted average number of non-redeemable common stock outstanding for the periods. Non-redeemable common stock includes the Founder Shares as these shares of common stock do not have any redemption features and do not participate in the income earned on the Trust Account. Accordingly, basic and diluted income per common share is calculated as follows:

 

   Three Months
Ended
June 30,
2021		   Six Months
Ended
June 30,
2021		 
Common stock subject to possible redemption        
Numerator: Net income allocable to common stock subject to possible redemption        
Accretion of interest income on marketable securities held in trust  $5,069   $10,081 
Less: interest available to be withdrawn for payment of taxes   (5,069)   (10,081)
Net income allocable to Common Stock subject to possible redemption  $
—
   $— 
Denominator: Weighted Average Redeemable Common Stock          
Redeemable Common Stock, Basic and Diluted   18,436,292    18,263,412 
Basic and Diluted net income per share, Redeemable Common Stock  $0.00   $0.00 
           
Non-Redeemable Common Stock          
Numerator: Net (Loss) Income minus Redeemable Net Earnings          
Net income  $(409,152)  $3,172,181 
Redeemable Net Earnings   
—
    — 
Non-Redeemable Net income  $(409,152)  $3,172,181 
Denominator: Weighted Average Non-Redeemable Common Stock          
Basic and diluted weighted average shares outstanding, Common Stock   6,719,958    6,892,838 
Basic and diluted net income per share, Common Stock  $(0.06)  $0.46 

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

 

Fair Value Measurements

 

Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:

 

  ● Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;

 

  ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

 

  ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

9

 

 

Fair Value of Financial Instruments

 

The fair value of the Company’s assets and liabilities, (excluding the warrant liability) which qualify as financial instruments under the Financial Accounting Standards Board (“FASB”) ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the balance sheet primarily due to their short-term nature.

 

Derivative Financial Instruments

 

The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. The Company’s derivative instruments are recorded at fair value and re-valued at each reporting date, with changes in the fair value reported in the statements of operations. Derivative assets and liabilities are classified on the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. The Company has determined the warrants are a derivative instrument. As the warrants meet the definition of a derivative the warrants are measured at fair value at issuance and at each reporting date in accordance with ASC 820, Fair Value Measurement, with changes in fair value recognized in the statement of operations in the period of change. In accordance with ASC 825-10 “Financial Instruments”, the Company has concluded that a portion of the transaction costs which directly related to the IPO and the Private Placement, should be allocated to the Warrants based on their relative fair value against total proceeds, and recognized as transaction costs in the statement of operations.

 

Recent Accounting Pronouncements

 

Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

 

Note 3 — Initial Public Offering

 

Public Units

 

On December 28, 2020, the Company sold 17,500,000 Units, at a purchase price of $10.00 per Unit. Each Unit consists of one share of Common Stock, par value $0.0001 per share, one redeemable warrant (the “Public Warrants”) and one right. Each right entitles the holder thereof to receive one-twentieth (1/20) of a share of common stock upon consummation of our initial business combination.

 

On December 28, 2020, the Underwriters fully exercised the over-allotment option by purchasing 2,625,000 Units (the “Over-Allotment Units”), generating aggregate of gross proceeds of $26,250,000.

 

Note 4 — Private Placement

 

Simultaneously with the closing of the IPO, the Sponsor purchased an aggregate of 18,000,000 warrants at a price of $0.50 per warrant ($9,000,000 in the aggregate), each exercisable to purchase one-half of a share common stock at a price of $11.50 per whole share, in a private placement that closed simultaneously with the closing of this offering. A portion of the purchase price of the private placement warrants was added to the proceeds from this offering to be held in the Trust Account

 

Note 5 — Related Party Transactions

 

Founder Shares

 

In August 2020, the Sponsor paid $25,000, or approximately $0.007 per share, to cover certain offering costs in consideration for 3,593,750 shares of common stock, par value $0.0001 (the “Founder Shares”). On December 3, 2020, the Company declared a share dividend of  0.36 for each outstanding share, resulting in 4,887,500 shares outstanding, and on December 22, 2020 the Company declared a share dividend of  0.03 resulting in 5,031,250 shares which includes an aggregate of up to 656,250 shares that are subject to forfeiture to the extent that the underwriters’ over-allotment option is not exercised in full or in part, and up to an aggregate of 1,006,250 shares of common stock (or 875,000 shares of common stock to the extent that the underwriters’ over-allotment is not exercised, pro rata) that are subject to forfeiture to the extent that rights are exercised upon consummation of an initial business combination. In connection with the underwriters’ fully exercise of their over-allotment option on December 30, 2020 (see Note 3), the 656,250 shares were no longer subject to forfeiture.

 

10

 

 

The founder shares were placed into an escrow account maintained by Continental Stock Transfer & Trust Company acting as escrow agent. 50% of these shares will not be transferred, assigned, sold or released from escrow until the earlier of (i) 6 months after the date of the consummation of the Company’s initial business combination or (ii) the date on which the closing price of the Company’s shares of common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing after its initial business combination and the remaining 50% of the founder shares will not be transferred, assigned, sold or released from escrow until 6 months after the date of the consummation of the Company’s initial business combination, or earlier, in either case, if, subsequent to its initial business combination, the Company consummates a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of its stockholders having the right to exchange their shares of common stock for cash, securities or other property.

 

During the escrow period, the holders of these shares will not be able to sell or transfer their securities except (1) to any persons (including their affiliates and stockholders) participating in the private placement of the private warrants, officers, directors, stockholders, employees and members of the Company’s sponsor and its affiliates, (2) amongst initial stockholders or their respective affiliates, or to the Company’s officers, directors, advisors and employees, (3) if a holder is an entity, as a distribution to its, partners, stockholders or members upon its liquidation, (4) by bona fide gift to a member of the holder’s immediate family or to a trust, the beneficiary of which is a holder or a member of a holder’s immediate family, for estate planning purposes, (5) by virtue of the laws of descent and distribution upon death, (6) pursuant to a qualified domestic relations order, (7) by certain pledges to secure obligations incurred in connection with purchases of the Company’s securities, (8) by private sales at prices no greater than the price at which the shares were originally purchased or (9) for the cancellation of up to 656,250 shares of common stock subject to forfeiture to the extent that the underwriters’ over-allotment is not exercised in full or in part or in connection with the consummation of the Company’s initial business combination, in each case (except for clause 9 or with the Company’s prior consent) where the transferee agrees to the terms of the escrow agreement and the insider letter.

 

Promissory Note — Related Party

 

The Sponsor agreed to loan the Company an aggregate of up to $500,000 to cover expenses related to the Initial Public Offering pursuant to a promissory note (the “Note”). This loan is non-interest bearing and payable on the earlier of March 31, 2021 or the completion of the Initial Public Offering. On January 13, 2021, the Company paid the $228,758 balance on the note from the proceeds of the IPO. As of June 30, 2021, the Company had no balance under the Note.

 

Working Capital Loans

 

In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). Each loan would be evidenced by a promissory note. The notes would be repaid upon consummation of the Company’s initial business combination, without interest. As of June 30, 2021 and December 31, 2020, the Company had no borrowings under the Working Capital Loans.

 

Administrative Service Fee

 

Commencing on the date of the final prospectus, the Company has agreed to pay the Sponsor a total of $20,000 per month for office space, utilities and secretarial support. Upon completion of the initial Business Combination or the Company’s liquidation, the Company will cease paying these monthly fees. The Company has incurred $120,000 and accrued $110,000 of administrative service fees for the six months ended June 30, 2021 and any unpaid amounts are accrued in Due to related party.

 

Note 6 — Commitments and Contingencies

 

Underwriting Agreement

 

The underwriters were entitled to deferred underwriting fee of 3.5% of the gross proceeds of the IPO, or $7,043,750 in the aggregate. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.

 

Registration Rights

 

The holders of the Company’s insider shares issued and outstanding on the date of this prospectus, as well as the holders of the private warrants (and underlying securities) will be entitled to registration rights pursuant to an agreement to be signed prior to or on the effective date of this offering. The holders of a majority of these securities are entitled to make up to two demands that the Company registers such securities. The holders of the majority of the insider shares can elect to exercise these registration rights at any time commencing three months prior to the date on which these shares of common stock are to be released from escrow. The holders of a majority of the private warrants (and underlying securities) can elect to exercise these registration rights at any time after the Company consummates a business combination. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the Company’s consummation of a business combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

 

11

 

 

Note 7 — Stockholders’ Equity

 

Preferred Stock — The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 and with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of June 30, 2021 and December 31, 2020, there was no preferred stock issued or outstanding.

 

Common Stock — The Company is authorized to issue 60,000,000 shares of common stock with a par value of $0.0001 per share. Holders are entitled to one vote for each share of common stock. As of June 30, 2021, 2021 and December 31, 2020, there were 6,760,023 and 7,071,551 shares of common stock issued and outstanding, excluding 18,396,227 and 18,084,699 shares of common stock subject to possible redemption, respectively.

 

Rights —Except in cases where the Company is not the surviving company in a business combination, each holder of a right will automatically receive one-twentieth (1/20) of a share of common stock upon consummation of the initial business combination. In the event the Company will not be the surviving company upon completion of the initial business combination, each holder of a right will be required to affirmatively convert his, her or its rights in order to receive the one-twentieth (1/20) of a share underlying each right upon consummation of the business combination. The Company will not issue fractional shares in connection with an exchange of rights. Fractional shares will either be rounded down to the nearest whole share or otherwise addressed in accordance with the applicable provisions of the Delaware General Corporation Law. As a result, holders must hold rights in multiples of 20 in order to receive shares for all rights upon closing of a business combination. If the Company is unable to complete an initial business combination within the required time period and the Company redeems the public shares for the funds held in the trust account, holders of rights will not receive any of such funds for their rights and the rights will expire worthless.

 

Note 8 — Warrants

 

Public Warrants

 

 Each warrant entitles the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $11.50 per whole share, subject to adjustment as described in this prospectus. Each right entitles the holder thereof to receive one-twentieth (1/20) of a share of common stock upon consummation of our initial business combination. Pursuant to the warrant agreement, a warrant holder may exercise its public warrants only for a whole number of shares. This means that only an even number of public warrants may be exercised at any given time by a warrant holder.

 

The Company may call the warrants for redemption (except the Private Warrants):

 

  ● in whole and not in part;
     
  ● at a price of $0.01 per warrant;
     
  ● upon not less than 30 days’ prior written notice of redemption (the “30-day redemption period”) to each warrant holder; and
     
  ● if and only if, there is a current registration statement in effect with respect to the shares of common stock underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption.

 

If the Company calls the warrants for redemption as described above, its management will have the option to require all holders that wish to exercise warrants to do so on a “cashless basis.” In such event, each holder would pay the exercise price by surrendering the warrants for that number of shares of common stock equal to the quotient obtained by dividing (x) the product of the number of shares of common stock underlying the warrants, multiplied by the difference between the exercise price of the warrants and the “fair market value” (defined below) by (y) the fair market value. The “fair market value” shall mean the average reported last sale price of the Company’s common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. Whether the Company will exercise our option to require all holders to exercise their warrants on a “cashless basis” will depend on a variety of factors including the price of our common shares at the time the warrants are called for redemption, its cash needs at such time and concerns regarding dilutive share issuances. 

 

12

 

 

If (x) the Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of its initial business combination at an issue price or effective issue price of less than $9.50 per share of common stock (with such issue price or effective issue price to be determined in good faith by its board of directors, and in the case of any such issuance to its sponsor, initial stockholders or their affiliates, without taking into account any founders’ shares held by them prior to such issuance), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of our initial business combination on the date of the consummation of our initial business combination (net of redemptions), and (z) the Market Value is below $9.50 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of (i) the Market Value or (ii) the price at which the Company issues the additional shares of common stock or equity-linked securities and the $16.50 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to 165% of the Market Value. The warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price, by certified or official bank check payable to the Company, for the number of warrants being exercised. The warrant holders do not have the rights or privileges of holders of shares of common stock and any voting rights until they exercise their warrants and receive shares of common stock. After the issuance of shares of common stock upon exercise of the warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by stockholders.

 

Private Warrants

 

The private warrants are identical to the warrants sold as part of the public units in this offering except that the private warrants will be non-redeemable and may be exercised on a cashless basis, in each case so long as they continue to be held by the initial purchasers or their permitted transferees. Additionally, if public units or shares of common stock are purchased by any of the directors, officers or initial stockholders, they will be entitled to funds from the trust account to the same extent as any public stockholder upon our liquidation but will not have redemption rights related thereto.

 

Note 9 — Fair Value Measurements

 

The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis at June 30, 2021, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:

 

   June 30,             
   2021   (Level 1)   (Level 2)   (Level 3) 
Assets:                
Mutual Funds held in Trust Account  $203,272,741   $203,272,741   $
—
   $
—
 
   $203,272,741   $203,272,741   $
—
   $
—
 
Liabilities:                    
Private Warrant Liability  $6,631,815   $
—
   $
—
    6,631,815 
   $6,631,815   $
—
   $
—
   $6,631,815 

 

13

 

 

The Warrants are accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liabilities on the Condensed Balance Sheet. The warrant liabilities were measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrant liabilities in the Condensed Statement of Operations.

 

The Company established the initial fair value of the Private Warrants on December 28, 2020, the date of the Company’s Initial Public Offering, and revalued on December 31, 2020 and on June 30, 2021 , using a Monte Carlo simulation model. The Warrants were classified as Level 3 at the initial measurement date due to the use of unobservable inputs.

  

The key inputs into the Monte Carlo simulation as of December 31, 2020 and June 30, 2021 were as follows:

 

Inputs  December 31,
2020		   June 30,
2021		 
Risk-free interest rate   0.52%   0.98%
Expected term remaining (years)   6.12    5.63 
Expected volatility   24.2%   13.4%
Stock price  $9.625   $9.900 

 

The change in the fair value of the Private Warrant liability for the period ended June 30, 2021 is summarized as follows:

 

Fair value at December 31, 2020  $10,763,361 
Change in fair value   (4,131,546)
Fair Value at June 30, 2021  $6,631,815 

 

Note 10 — Subsequent Events

 

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.

 

14

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

References in this report (the “Quarterly Report”) to “we,” “us” or the “Company” refer to Viveon Health Acquisition Corp. References to our “management” or our “management team” refer to our officers and directors, and references to the “Sponsor” refer to Viveon Health, LLC. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the financial statements and the notes thereto contained elsewhere in this Quarterly Report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

 

Special Note Regarding Forward-Looking Statements

 

This Quarterly Report includes “forward-looking statements” that are not historical facts and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. All statements, other than statements of historical fact included in this Quarterly Report including, without limitation, statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding the Company’s financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. Words such as “expect,” “believe,” “anticipate,” “intend,” “estimate,” “seek” and variations and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management’s current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors section of the Company’s final prospectus for its Initial Public Offering filed with the U.S. Securities and Exchange Commission (the “SEC”). The Company’s securities filings can be accessed on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

 

Overview

 

We are a blank check company formed under the laws of the State of Delaware on August 7, 2020 for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more target businesses. Although we are not limited to a particular industry or geographic region for purposes of consummating an initial business combination, we intend to focus on businesses that have their primary operations located in North America in the healthcare industry. We intend to utilize cash derived from the proceeds of our initial public offering in effecting our Initial Business Combination.

 

The issuance of additional shares in connection with an initial business combination:

 

  ● may significantly dilute the equity interest of our investors in this offering who would not have pre-emption rights in respect of any such issuance;
     
  ● may subordinate the rights of holders of shares of common stock if we issue shares of preferred stock with rights senior to those afforded to our shares of common stock;
     
  ● will likely cause a change in control if a substantial number of our shares of common stock are issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and most likely will also result in the resignation or removal of our present officers and directors; and
     
  ● may adversely affect prevailing market prices for our securities.

 

Similarly, if we issue debt securities, it could result in:

 

  ● default and foreclosure on our assets if our operating revenues after our Initial Business Combination are insufficient to pay our debt obligations;

 

  ● acceleration of our obligations to repay the indebtedness even if we have made all principal and interest payments when due if the debt security contains covenants that required the maintenance of certain financial ratios or reserves and we breach any such covenant without a waiver or renegotiation of that covenant;

 

15

 

 

  ● our immediate payment of all principal and accrued interest, if any, if the debt security is payable on demand;
     
  ● our inability to obtain additional financing, if necessary, if the debt security contains covenants restricting our ability to obtain additional financing while such security is outstanding; and
     
  ● limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, execution of our strategy and other purposes and other disadvantages compared to our competitors who have less debt.

 

We expect to continue to incur significant costs in the pursuit of our acquisition plans. We cannot assure you that our plans to complete our Initial Business Combination will be successful.

 

Results of Operations

 

We have neither engaged in any operations nor generated any revenues to date. Our only activities from August 7, 2020 (inception) through June 30, 2021 were organizational activities, those necessary to prepare for the Initial Public Offering, described below, and, after our Initial Public Offering, identifying a target company for a Business Combination. We do not expect to generate any operating revenues until after the completion of our Business Combination. We generate non-operating income in the form of interest income on marketable securities held after the Initial Public Offering. We incur expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses.

 

For the six months ended June 30, 2021, we had net income of $3,172,181, which consisted of interest income on marketable securities held in the Trust Account and on the operating bank account of $10,192 and a change in fair value of warrant liability of $4,131,546, partially offset by operating costs of $969,557.  

 

Liquidity and Capital Resources

 

For the six months ended June 30, 2021, net cash used in operating activities was $1,446,696. Net income of $3,172,181 was impacted by interest earned on marketable securities held in the Trust Account of $10,081, a change in fair value of warrant liability of $4,131,546, and changes in operating assets and liabilities, which used $477,250 of cash from operating activities.

 

As of June 30, 2021, we had cash and marketable securities in the Trust Account of $203,272,741 (including approximately $10,081 of interest income). We intend to use substantially all of the funds held in the Trust Account, including any amounts representing interest earned on the Trust Account (less taxes payable and deferred underwriting commissions) to complete our Initial Business Combination. We may withdraw interest to pay taxes. During the period ended June 30, 2021, we did not withdraw any of interest income from the Trust Account to pay for franchise and income taxes. To the extent that our capital stock or debt is used, in whole or in part, as consideration to complete our Initial Business Combination, the remaining proceeds held in the Trust Account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies.

 

As of June 30, 2021, we had cash and cash equivalents of $1,056,622 outside of the Trust Account. We intend to use the funds held outside the Trust Account primarily to identify and evaluate target businesses, perform business due diligence on prospective target businesses, travel to and from the offices, plants or similar locations of prospective target businesses or their representatives or owners, review corporate documents and material agreements of prospective target businesses, and structure, negotiate and complete our Initial Business Combination.

 

In order to fund working capital deficiencies or finance transaction costs in connection with a Business Combination, our initial shareholders, officers and directors or their affiliates may, but are not obligated to, loan us funds as may be required. If we complete a Business Combination, we would repay such loaned amounts. In the event that a Business Combination does not close, we may use a portion of the working capital held outside the Trust Account to repay such loaned amounts but no proceeds from our Trust Account would be used for such repayment.

 

As of June 30, 2021, we had $1,056,622 in our operating bank accounts, $203,272,741 in securities held in the Trust Account to be used for a Business Combination or to repurchase or redeem our common stock in connection therewith and working capital of $1,157,386, which excludes $47,334 of franchise taxes payable that will be paid from interest earned on the Trust Account.

 

16

 

 

We may need to raise additional capital through loans or additional investments from our Sponsor, or officers or directors. Our Sponsor, officers and directors may, but are not obligated to, loan us funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet our working capital needs.

 

Off-Balance Sheet Arrangements

 

We did not have any off-balance sheet arrangements as of June 30, 2021.

 

Contractual Obligations

 

We do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities other than an agreement to pay an affiliate of our sponsor a monthly fee of $20,000 for office space, utilities and secretarial and administrative support. We began incurring these fees on December 22, 2020 and will continue to incur these fees monthly until the earlier of the completion of the Business Combination and our liquidation.

 

The underwriters are entitled to a deferred fee of $0.35 per Unit, or $7,043,750. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that we complete a Business Combination, subject to the terms of the underwriting agreement.

 

In addition, subject to certain conditions, we granted Chardan, for a period of 12 months after the date of the consummation of a Business Combination, a right of first refusal to act as book-running managing underwriter or placement agent, with at least 30% of the economics, for any and all future public and private equity, convertible and debt offerings. In accordance with FINRA Rule 5110(f)(2)(E)(i), such right of first refusal shall not have a duration of more than three years from the effective date of the registration statement related to the Initial Public Offering.

 

Critical Accounting Policies

 

The preparation of condensed consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and income and expenses during the periods reported. Actual results could materially differ from those estimates. We have identified the following critical accounting policies:

 

Common Stock Subject to Possible Redemption

 

We account for common stock subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that feature redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. Our common stock features certain redemption rights that are considered to be outside of our control and subject to occurrence of uncertain future events. Accordingly, common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ equity section of our condensed consolidated balance sheets.

 

Net Income Per Common Share

 

We apply the two-class method in calculating earnings per share. Common stock subject to possible redemption which is not currently redeemable and is not redeemable at fair value, have been excluded from the calculation of basic net loss per common share since such shares, if redeemed, only participate in their pro rata share of the Trust Account earnings. Our net income is adjusted for the portion of income that is attributable to common stock subject to possible redemption, as these shares only participate in the earnings of the Trust Account and not our income or losses.

 

Recent Accounting Standards

 

Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on our condensed consolidated financial statements.

 

17

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

As of June 30, 2021, we were not subject to any market or interest rate risk. The net proceeds held in the Trust Account have been invested in U.S. government treasury bills, notes or bonds with a maturity of 180 days or less, or in certain money market funds that invest solely in U.S. treasuries. Due to the short-term nature of these investments, we believe there will be no associated material exposure to interest rate risk.

 

Item 4. Controls and Procedures

 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

 

Evaluation of Disclosure Controls and Procedures

 

On April 12, 2021, the Acting Director of the Division of Corporation Finance and Acting Chief Accountant of the SEC together issued a statement regarding the accounting and reporting considerations for warrants issued by special purpose acquisition companies entitled “Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (“SPACs”)” (the “SEC Statement”).

 

As a result of these developments, the Company has reviewed its treatment of the Warrants and has filed its Amendment No. 1 to the Annual Report on Form 10-K filed on July 2, 2021 (the “10-K/A”). The 10-K/A provided for the reclassification of the private warrants as a liability for the affected period as described therein. Management concluded that a deficiency in internal control over financial reporting existed relating to the accounting treatment for complex financial instruments and that the failure to properly account for such instruments constituted a material weakness. This material weakness resulted in the need to restate the 10-K/A.

 

As required by Rules 13a-15 and 15d-15 under the Exchange Act, our Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2021. Based upon their evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rules 13a-15 (e) and 15d-15 (e) under the Exchange Act) were not effective, due solely to the material weakness in our internal control over financial reporting described above. In light of this material weakness, we performed additional analysis as deemed necessary to ensure that our financial statements were prepared in accordance with U.S. generally accepted accounting principles.

 

Changes in Internal Control Over Financial Reporting

 

Other than as described below, there was no change in our internal control over financial reporting that occurred during the fiscal quarter of 2021 covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. In light of the material weakness, we plan to enhance our processes to identify and appropriately apply applicable accounting requirements to better evaluate and understand the nuances of the complex accounting standards that apply to our financial statements. Our plans at this time include providing enhanced access to accounting literature, research materials and documents and increased communication among our personnel and third-party professionals with whom we consult regarding complex accounting applications. The elements of our remediation plan can only be accomplished over time, and we can offer no assurance that these initiatives will ultimately have the intended effects. 

 

18

 

 

PART II - OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

None.

 

ITEM 1A. RISK FACTORS

 

Factors that could cause our actual results to differ materially from those in this Quarterly Report are any of the risks described in our final prospectus for our Initial Public Offering filed with the SEC on December 22, 2020. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

On December 28, 2020, we consummated the IPO of 17,500,000 units (the “Units” and, with respect to the common stock included in the Units being offered, the “public share”), at $10.00 per Unit, generating gross proceeds of $175,000,000. Each Unit consists of one share of common stock, par value $0.0001, one warrant to purchase one-half of one share of common stock, and one right to receive one-twentieth (1/20) of a share of common stock upon the consummation of an initial business combination. We granted the underwriters a 45-day option to purchase up to an additional 2,550,000 units (over and above the 17,500,000 units referred to above) solely to cover over-allotments, if any.

 

On December 30, 2020, the underwriters exercised the over-allotment option in full, and the closing of the sale of the additional Units pursuant to the over-allotment option occurred on December 30, 2020. The issuance by the Company of 2,625,000 over-allotment option units at a price of $10.00 per unit resulted in gross proceeds of $26,250,000. Simultaneously with the closing of the IPO, we consummated a private placement with Viveon Health LLC, our sponsor, of 18,000,000 warrants (the “Private Warrants”), at a price of $0.50 per Private Warrant, to purchase 9,000,000 shares of Common Stock, generating total proceeds of $9,000,000. 

 

As of June 30, 2021, a total of $203,262,500 of the net proceeds from the IPO (including the over-allotment option units) and the Private Warrants were deposited in a trust account established for the benefit of the Company’s public shareholders.

 

We intend to use substantially all of the net proceeds of the IPO, including the funds held in the trust account, in connection with our initial business combination and to pay our expenses relating thereto, including a deferred underwriting commission payable to Chardan Capital Markets, LLC in an amount equal to 3.5% of the total gross proceeds raised in the IPO upon consummation of our initial business combination. To the extent that our capital stock is used in whole or in part as consideration to effect our initial business combination, the remaining proceeds held in the trust account as well as any other net proceeds not expended will be used as working capital to finance the operations of the target business. Such working capital funds could be used in a variety of ways including continuing or expanding the target business’ operations, for strategic acquisitions and for marketing, research and development of existing or new products. Such funds could also be used to repay any operating expenses or finders’ fees which we had incurred prior to the completion of our initial business combination if the funds available to us outside of the trust account were insufficient to cover such expenses.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

None.

 

19

 

 

ITEM 6. EXHIBITS

 

The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.

 

No.   Description of Exhibit  
31.1*   Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*   Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**   Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**   Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*   Inline XBRL Instance Document.
101.SCH*   Inline XBRL Taxonomy Extension Schema Document.
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104*   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

* Filed herewith.
** Furnished.

 

20

 

 

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  VIVEON HEALTH ACQUISITION CORP.
     
Date: August 16, 2021 By: /s/ Jagi Gill
  Name:  Jagi Gill
  Title: Chief Executive Officer
    (Principal Executive Officer)
     
Date: August 16, 2021 By: /s/ Rom Papadopoulos
  Name: Rom Papadopoulos
  Title: Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

 

21

 

 

false --12-31 Q2 0001823857 0001823857 2021-01-01 2021-06-30 0001823857 2021-08-16 0001823857 2021-06-30 0001823857 2020-12-31 0001823857 2021-04-01 2021-06-30 0001823857 us-gaap:CommonStockMember 2020-12-31 0001823857 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001823857 us-gaap:RetainedEarningsMember 2020-12-31 0001823857 us-gaap:CommonStockMember 2021-01-01 2021-06-30 0001823857 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-06-30 0001823857 us-gaap:RetainedEarningsMember 2021-01-01 2021-06-30 0001823857 us-gaap:CommonStockMember 2021-06-30 0001823857 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001823857 us-gaap:RetainedEarningsMember 2021-06-30 0001823857 us-gaap:CommonStockMember 2021-03-31 0001823857 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001823857 us-gaap:RetainedEarningsMember 2021-03-31 0001823857 2021-03-31 0001823857 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001823857 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001823857 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001823857 us-gaap:IPOMember 2021-01-01 2021-06-30 0001823857 us-gaap:IPOMember 2021-06-30 0001823857 2020-08-07 2020-12-31 0001823857 us-gaap:IPOMember 2020-12-05 2020-12-28 0001823857 us-gaap:IPOMember 2020-12-28 0001823857 us-gaap:OverAllotmentOptionMember 2020-12-05 2020-12-28 0001823857 us-gaap:PrivatePlacementMember 2021-01-01 2021-06-30 0001823857 us-gaap:PrivatePlacementMember 2021-06-30 0001823857 vhaq:FounderSharesMember 2020-08-07 2020-08-31 0001823857 vhaq:FounderSharesMember 2020-08-31 0001823857 vhaq:FounderSharesMember 2020-11-20 2020-12-03 0001823857 2020-12-03 0001823857 vhaq:FounderSharesMember 2020-12-05 2020-12-22 0001823857 us-gaap:OverAllotmentOptionMember 2020-12-05 2020-12-22 0001823857 us-gaap:OverAllotmentOptionMember 2020-12-05 2020-12-30 0001823857 vhaq:FounderSharesMember 2021-01-01 2021-06-30 0001823857 vhaq:SponsorMember 2021-01-01 2021-06-30 0001823857 vhaq:SponsorMember 2021-01-01 2021-06-30 0001823857 vhaq:MutualFundsHeldInTrustAccountMember 2021-06-30 0001823857 vhaq:MutualFundsHeldInTrustAccountMember us-gaap:FairValueInputsLevel1Member 2021-06-30 0001823857 vhaq:MutualFundsHeldInTrustAccountMember us-gaap:FairValueInputsLevel2Member 2021-06-30 0001823857 vhaq:MutualFundsHeldInTrustAccountMember us-gaap:FairValueInputsLevel3Member 2021-06-30 0001823857 us-gaap:FairValueInputsLevel1Member 2021-06-30 0001823857 us-gaap:FairValueInputsLevel2Member 2021-06-30 0001823857 us-gaap:FairValueInputsLevel3Member 2021-06-30 0001823857 vhaq:PrivatePlacementWarrantsLiabilityMember 2021-01-01 2021-06-30 0001823857 vhaq:PrivatePlacementWarrantsLiabilityMember us-gaap:FairValueInputsLevel1Member 2021-01-01 2021-06-30 0001823857 vhaq:PrivatePlacementWarrantsLiabilityMember us-gaap:FairValueInputsLevel2Member 2021-01-01 2021-06-30 0001823857 vhaq:PrivatePlacementWarrantsLiabilityMember us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-06-30 0001823857 us-gaap:FairValueInputsLevel1Member 2021-01-01 2021-06-30 0001823857 us-gaap:FairValueInputsLevel2Member 2021-01-01 2021-06-30 0001823857 us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-06-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure
EX-31.1 2 f10q0621ex31-1_viveonhealth.htm CERTIFICATION

Exhibit 31.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Jagi Gill, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Viveon Health Acquisition Corp.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; and
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
     
    Date: August 16, 2021

 

  /s/ Jagi Gill
  Jagi Gill
  Chief Executive Officer
  (Principal executive officer)

 

 EX-31.2 3 f10q0621ex31-2_viveonhealth.htm CERTIFICATION

Exhibit 31.2

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Rom Papadopoulos, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Viveon Health Acquisition Corp.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
    
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; and
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
     
    Date: August 16, 2021

 

  /s/ Rom Papadopoulos
  Rom Papadopoulos
  Chief Financial Officer
  (Principal financial and accounting officer)

 

 EX-32 4 f10q0621ex32_viveonhealth.htm CERTIFICATION

Exhibit 32

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Viveon Health Acquisition Corp. (the “Company”) on Form 10-Q for the quarter ended June 30, 2021 as filed with the Securities and Exchange Commission (the “Report”), each of the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

  1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.
      
    Date: August 16, 2021

 

  /s/ Jagi Gill
  Jagi Gill
  Chief Executive Officer
  (Principal executive officer)

 

    Date: August 16, 2021

 

  /s/ Rom Papadopoulos
  Rom Papadopoulos
  Chief Financial Officer
  (Principal financial and accounting officer)

 

 EX-101.SCH 5 vhaq-20210630.xsd XBRL SCHEMA FILE 001 - Statement - Condensed Balance Sheets link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Condensed Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Condensed Statement of Changes in Stockholders’ Equity (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Condensed Statement of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - Organization and Business Operation link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Initial Public Offering link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Private Placement link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Stockholders’ Equity link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Warrants link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Fair Value Measurements link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Organization and Business Operation (Details) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Significant Accounting Policies (Details) - Schedule of net loss per common share, basic and diluted, for redeemable and non-redeemable common stock link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Initial Public Offering (Details) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Private Placement (Details) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Stockholders’ Equity (Details) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Warrants (Details) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value on a recurring basis link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Fair Value Measurements (Details) - Schedule of key inputs into the Monte Carlo simulation link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Fair Value Measurements (Details) - Schedule of change in fair value of private placement warrant liabilities link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 6 vhaq-20210630_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 vhaq-20210630_def.xml XBRL DEFINITION FILE EX-101.LAB 8 vhaq-20210630_lab.xml XBRL LABEL FILE EX-101.PRE 9 vhaq-20210630_pre.xml XBRL PRESENTATION FILE XML 10 f10q0621_viveonhealthacq_htm.xml IDEA: XBRL DOCUMENT 0001823857 2021-01-01 2021-06-30 0001823857 2021-08-16 0001823857 2021-06-30 0001823857 2020-12-31 0001823857 2021-04-01 2021-06-30 0001823857 us-gaap:CommonStockMember 2020-12-31 0001823857 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001823857 us-gaap:RetainedEarningsMember 2020-12-31 0001823857 us-gaap:CommonStockMember 2021-01-01 2021-06-30 0001823857 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-06-30 0001823857 us-gaap:RetainedEarningsMember 2021-01-01 2021-06-30 0001823857 us-gaap:CommonStockMember 2021-06-30 0001823857 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001823857 us-gaap:RetainedEarningsMember 2021-06-30 0001823857 us-gaap:CommonStockMember 2021-03-31 0001823857 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001823857 us-gaap:RetainedEarningsMember 2021-03-31 0001823857 2021-03-31 0001823857 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001823857 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001823857 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001823857 us-gaap:IPOMember 2021-01-01 2021-06-30 0001823857 us-gaap:IPOMember 2021-06-30 0001823857 2020-08-07 2020-12-31 0001823857 us-gaap:IPOMember 2020-12-05 2020-12-28 0001823857 us-gaap:IPOMember 2020-12-28 0001823857 us-gaap:OverAllotmentOptionMember 2020-12-05 2020-12-28 0001823857 us-gaap:PrivatePlacementMember 2021-01-01 2021-06-30 0001823857 us-gaap:PrivatePlacementMember 2021-06-30 0001823857 vhaq:FounderSharesMember 2020-08-07 2020-08-31 0001823857 vhaq:FounderSharesMember 2020-08-31 0001823857 vhaq:FounderSharesMember 2020-11-20 2020-12-03 0001823857 2020-12-03 0001823857 vhaq:FounderSharesMember 2020-12-05 2020-12-22 0001823857 us-gaap:OverAllotmentOptionMember 2020-12-05 2020-12-22 0001823857 us-gaap:OverAllotmentOptionMember 2020-12-05 2020-12-30 0001823857 vhaq:FounderSharesMember 2021-01-01 2021-06-30 0001823857 vhaq:SponsorMember 2021-01-01 2021-06-30 0001823857 vhaq:SponsorMember 2021-01-01 2021-06-30 0001823857 vhaq:MutualFundsHeldInTrustAccountMember 2021-06-30 0001823857 vhaq:MutualFundsHeldInTrustAccountMember us-gaap:FairValueInputsLevel1Member 2021-06-30 0001823857 vhaq:MutualFundsHeldInTrustAccountMember us-gaap:FairValueInputsLevel2Member 2021-06-30 0001823857 vhaq:MutualFundsHeldInTrustAccountMember us-gaap:FairValueInputsLevel3Member 2021-06-30 0001823857 us-gaap:FairValueInputsLevel1Member 2021-06-30 0001823857 us-gaap:FairValueInputsLevel2Member 2021-06-30 0001823857 us-gaap:FairValueInputsLevel3Member 2021-06-30 0001823857 vhaq:PrivatePlacementWarrantsLiabilityMember 2021-01-01 2021-06-30 0001823857 vhaq:PrivatePlacementWarrantsLiabilityMember us-gaap:FairValueInputsLevel1Member 2021-01-01 2021-06-30 0001823857 vhaq:PrivatePlacementWarrantsLiabilityMember us-gaap:FairValueInputsLevel2Member 2021-01-01 2021-06-30 0001823857 vhaq:PrivatePlacementWarrantsLiabilityMember us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-06-30 0001823857 us-gaap:FairValueInputsLevel1Member 2021-01-01 2021-06-30 0001823857 us-gaap:FairValueInputsLevel2Member 2021-01-01 2021-06-30 0001823857 us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-06-30 shares iso4217:USD iso4217:USD shares pure 10-Q true 2021-06-30 2021 false 001-39827 VIVEON HEALTH ACQUISITION CORP. DE 85-2788202 c/o Gibson, Deal & Fletcher, PC Spalding Exchange 3953 Holcomb Bridge Road Suite 200 Norcross GA 30092 (404) -861-5393 Common Stock VHAQ NYSE Yes Yes Non-accelerated Filer true true false true 25156250 1056622 3096956 339671 660695 1396293 3757651 203272741 203262660 204669034 207020311 75767 958292 364880 228758 115806 5806 191573 1557736 7043750 7043750 6631815 10763361 13867138 19364847 18396227 18084699 185801895 182655456 0.0001 0.0001 1000000 1000000 0.0001 0.0001 60000000 60000000 6760023 6760023 7071551 7071551 676 707 3641297 6813454 1358028 -1814153 5000001 5000008 204669034 207020311 648124 969557 -648124 -969557 5069 10081 30 111 -233873 -4131546 238972 4141738 -409152 3172181 6719958 6892838 -0.06 0.46 18436292 18263412 0.00 0.00 7071551 707 6813454 -1814153 5000008 -25749 -25749 3172181 3172181 -311528 -31 -3146408 -3146439 6760023 676 3641297 1358028 5000001 6719513 672 3232152 1767180 5000004 -409152 -409152 40510 4 409145 409149 6760023 676 3641297 1358028 5000001 3172181 10081 -4131546 -321024 -908274 110000 -1446696 228758 -364880 -593638 -2040334 3096956 1056622 3146439 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 — Organization and Business Operations</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Viveon Health Acquisition Corp. (the “Company”) is a newly organized blank check company incorporated as a Delaware company on August 7, 2020. The Company was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities (“Business Combination”).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have neither engaged in any operations nor generated any revenues to date. Our only activities from August 7, 2020 (inception) through June 30, 2021 were organizational activities, those necessary to prepare for the Initial Public Offering, described below, and, after our Initial Public Offering, identifying a target company for a Business Combination. We do not expect to generate any operating revenues until after the completion of our Business Combination. We generate non-operating income in the form of interest income on marketable securities held after the Initial Public Offering. We incur expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses. The Company’s sponsor is Viveon Health LLC, a Delaware limited liability company (the “Sponsor”).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon closing of the IPO and the sale of the Over-Allotment Units, $203,262,500 (approximately $10.10 per Unit) from net offering proceeds of the sale of the Units in the IPO and the sale of the Private Warrants was placed in a trust account (the “Trust Account”) and invested in U.S. government securities, with a maturity of 180 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act, which invest only in direct U.S. government treasury obligations. Except with respect to interest earned on the funds held in the Trust Account that may be released to the Company to pay its tax obligations, the proceeds from the IPO will not be released from the Trust Account until the earliest to occur of (1) the completion of the Company’s initial Business Combination within 15 months and (2) the Company’s redemption of 100% of the outstanding public shares if the Company has not completed a business combination in the required time period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s management has broad discretion with respect to the specific application of the net proceeds of the IPO, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the assets held in the Trust Account (as defined below) (net of amounts disbursed to management for working capital purposes, if permitted, and excluding the amount of any deferred underwriting commissions) at the time of the agreement to enter into the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires an interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act 1940, as amended (the “Investment Company Act”).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with any proposed initial Business Combination, the Company will either (1) seek stockholder approval of such initial Business Combination at a meeting called for such purpose at which public stockholders may seek to convert their public shares, regardless of whether they vote for or against the proposed business combination, into their pro rata share of the aggregate amount then on deposit in the trust account (net of taxes payable) or (2) provide its public stockholders with the opportunity to sell their public shares to the Company by means of a tender offer (and thereby avoid the need for a stockholder vote) for an amount equal to their pro rata share of the aggregate amount then on deposit in the trust account (net of taxes payable), in each case subject to the limitations described herein.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Company determines to engage in a tender offer, such tender offer will be structured so that each public stockholder may tender any or all of his, her or its public shares rather than some pro rata portion of his, her or its shares. If enough stockholders tender their shares so that the Company is unable to satisfy any applicable closing condition set forth in the definitive agreement related to its initial Business Combination, or the Company is unable to maintain net tangible assets of at least $5,000,001, the Company will not consummate such initial Business Combination. The decision as to whether it will seek stockholder approval of a proposed business combination or will allow stockholders to sell their shares to the Company in a tender offer will be made by the Company based on a variety of factors such as the timing of the transaction or whether the terms of the transaction would otherwise require us to seek stockholder approval.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Company provides stockholders with the opportunity to sell their shares to it by means of a tender offer, it will file tender offer documents with the SEC which will contain substantially the same financial and other information about the initial Business Combination as is required under the SEC’s proxy rules. If the Company seeks stockholder approval of its initial Business Combination, the Company will consummate the business combination only if a majority of the outstanding shares of common stock present in person or by proxy at a meeting of the Company are voted in favor of the business combination.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding the foregoing redemption rights, if the Company seeks stockholder approval of its initial Business Combination and the Company does not conduct redemptions in connection with its initial Business Combination pursuant to the tender offer rules, the Amended and Restated Certificate of Incorporation will provide that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Exchange Act), will be restricted from redeeming its shares with respect to more than an aggregate of 20% of the shares sold in this offering, without the Company’s prior consent. The Company’s sponsor, officers and directors (the “initial stockholders”) have agreed not to propose any amendment to the Amended and Restated Certificate of Incorporation (a) that would modify the substance or timing of the Company’s obligation to provide for the redemption of its public shares in connection with an initial Business Combination or to redeem 100% of its public shares if the Company does not complete its initial Business Combination within 15 months from the closing of the IPO (the “Combination Period”) or (b) with respect to any other material provisions relating to stockholders’ rights or pre-initial Business Combination activity, unless the Company provide its public stockholders with the opportunity to redeem their shares of common stock in conjunction with any such amendment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Company is unable to complete its initial Business Combination within the Combination Period, the Company will: (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than five business days thereafter, redeem 100% of the outstanding public shares (including any public units in this offering or any public units or shares that its initial stockholders or their affiliates purchased in this offering or later acquired in the open market or in private transactions), which will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably practicable following such redemption, subject to the approval of the Company’s remaining holders of common stock and its board of directors, proceed to commence a voluntary liquidation and thereby a formal dissolution of the Company, subject (in the case of (ii) and (iii) above) to its obligations to provide for claims of creditors and the requirements of applicable law.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s initial stockholders agreed to waive their rights to liquidating distributions from the Trust Account with respect to any founder shares held by them if the Company fails to complete its initial Business Combination within the Combination Period. However, if the initial stockholders acquire public shares in or after the IPO, they will be entitled to liquidating distributions from the Trust Account with respect to such public shares if the Company fails.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks and Uncertainties </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management is currently continuing to evaluate the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity and Capital Resources</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2021, the Company had $1,056,622 of cash and cash equivalents held outside the Trust Account available for working capital needs. All remaining cash held in the Trust Account is generally unavailable for the Company’s use, prior to an initial business combination, and is restricted for use either in a Business Combination or to redeem common stock. As of June 30, 2021 and December 31, 2020, none of the amount in the Trust Account was available to be withdrawn as described above.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company anticipates that the $1,056,622 outside of the Trust Account as of June 30, 2021, will be sufficient to allow the Company to operate for at least the next 12 months from the issuance of the financial statements, assuming that a Business Combination is not consummated during that time. Until consummation of its Business Combination, the Company will be using the funds not held in the Trust Account, and any additional Working Capital Loans (as defined in Note 5) from the initial stockholders, the Company’s officers and directors, or their respective affiliates (which is described in Note 5), for identifying and evaluating prospective acquisition candidates, performing business due diligence on prospective target businesses, traveling to and from the offices, plants or similar locations of prospective target businesses, reviewing corporate documents and material agreements of prospective target businesses, selecting the target business to acquire and structuring, negotiating and consummating the Business Combination.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Emerging Growth Company</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is an “emerging growth company”, as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, Section 107 of the JOBS Act also provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company intends to take advantage of the benefits of this extended transition period.</span></p> 203262500 10.10 P180D 1 0.80 0.50 5000001 0.20 1 1 1056622 1056622 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 — Significant Accounting Policies</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of Presentation </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">The accompanying unaudited condensed financial statements should be read in conjunction with </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Company’s Annual Report on Form 10-K/A for the year ended December 31, 2020 as filed with the SEC on July 2, 2021, which contains the audited financial statements and notes thereto. The interim results for the six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any future interim periods.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash and Cash Equivalents</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The cash equivalents in the amount of $950,419 and $3,092,771, were held in money market funds as of June 30, 2021 and December 31, 2020, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Marketable Securities Held in Trust Account</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At June 30, 2021 and December 31, 2020, substantially all of the assets held in the Trust Account were held in mutual funds which invest in U.S. Treasury securities. The mutual fund assets in the amount of $203,272,741 and $203,262,660 were held in the Trust Account as of June 30, 2021 and December 31, 2020, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date for Private Warrants while the warrants are outstanding.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance and recorded as a warrant liability. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Stock Subject to Possible Redemption</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its common stock subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Common stock subject to mandatory redemption (if any) is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock feature certain redemption right that is considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet. At June 30, 2021 and December 31, 2020, 18,396,227 and 18,084,699 shares of common stock subject to possible redemption are presented as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income Taxes </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, “Income Taxes” (“ASC 740”). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of June 30, 2021. The Company’s management determined that the United States is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties for the three-month period ending June 30, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net Income Per Common Share</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. The calculation of diluted loss per common share does not consider the effect of the warrants issued in connection with the (i) IPO, (ii) exercise of over-allotment and (iii) Private Placement since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. The warrants are exercisable to purchase 19,062,500 shares of common stock in the aggregate.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s statement of operations includes a presentation of net income per share for common stock subject to possible redemption in a manner similar to the two-class method. Net income per common share, basic and diluted, for redeemable Common Stock is calculated by dividing the interest income earned on the Trust Account, net of applicable franchise and income taxes, by the weighted average number of redeemable common stock outstanding since original issuance.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reconciliation of Net Income per Common Share</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net income per common share, basic and diluted, for redeemable common stock is calculated by dividing the interest income earned on the Trust Account, by the weighted average number of redeemable common stock outstanding since original issuance. Net income per common stock, basic and diluted, for non-redeemable Common Stock is calculated by dividing the net income, adjusted for income attributable to redeemable common stock, by the weighted average number of non-redeemable common stock outstanding for the periods. Non-redeemable common stock includes the Founder Shares as these shares of common stock do not have any redemption features and do not participate in the income earned on the Trust Account. Accordingly, basic and diluted income per common share is calculated as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months<br/> Ended<br/> June 30, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six Months<br/> Ended<br/> June 30, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Common stock subject to possible redemption</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td>Numerator: Net income allocable to common stock subject to possible redemption</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; text-indent: 20pt">Accretion of interest income on marketable securities held in trust</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,069</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,081</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 20pt">Less: interest available to be withdrawn for payment of taxes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,069</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,081</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 40pt">Net income allocable to Common Stock subject to possible redemption</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 10pt">Denominator: Weighted Average Redeemable Common Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: 20pt">Redeemable Common Stock, Basic and Diluted</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">18,436,292</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">18,263,412</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt; text-indent: 10pt">Basic and Diluted net income per share, Redeemable Common Stock</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.00</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.00</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Non-Redeemable Common Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 10pt">Numerator: Net (Loss) Income minus Redeemable Net Earnings</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 20pt">Net income</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(409,152</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,172,181</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 20pt">Redeemable Net Earnings</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 40pt">Non-Redeemable Net income</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(409,152</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,172,181</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 10pt">Denominator: Weighted Average Non-Redeemable Common Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt; text-indent: 20pt">Basic and diluted weighted average shares outstanding, Common Stock</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">6,719,958</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">6,892,838</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: 10pt">Basic and diluted net income per share, Common Stock</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.06</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.46</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentration of Credit Risk</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value Measurements</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.4pt; text-align: justify; text-indent: -16.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value of Financial Instruments</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the Company’s assets and liabilities, (excluding the warrant liability) which qualify as financial instruments under the Financial Accounting Standards Board (“FASB”) ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the balance sheet primarily due to their short-term nature.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Derivative Financial Instruments</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. The Company’s derivative instruments are recorded at fair value and re-valued at each reporting date, with changes in the fair value reported in the statements of operations. Derivative assets and liabilities are classified on the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. The Company has determined the warrants are a derivative instrument. As the warrants meet the definition of a derivative the warrants are measured at fair value at issuance and at each reporting date in accordance with ASC 820, Fair Value Measurement, with changes in fair value recognized in the statement of operations in the period of change. In accordance with ASC 825-10 “Financial Instruments”, the Company has concluded that a portion of the transaction costs which directly related to the IPO and the Private Placement, should be allocated to the Warrants based on their relative fair value against total proceeds, and recognized as transaction costs in the statement of operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent Accounting Pronouncements</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of Presentation </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">The accompanying unaudited condensed financial statements should be read in conjunction with </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Company’s Annual Report on Form 10-K/A for the year ended December 31, 2020 as filed with the SEC on July 2, 2021, which contains the audited financial statements and notes thereto. The interim results for the six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any future interim periods.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash and Cash Equivalents</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The cash equivalents in the amount of $950,419 and $3,092,771, were held in money market funds as of June 30, 2021 and December 31, 2020, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 950419 3092771 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Marketable Securities Held in Trust Account</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At June 30, 2021 and December 31, 2020, substantially all of the assets held in the Trust Account were held in mutual funds which invest in U.S. Treasury securities. The mutual fund assets in the amount of $203,272,741 and $203,262,660 were held in the Trust Account as of June 30, 2021 and December 31, 2020, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 203272741 203262660 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date for Private Warrants while the warrants are outstanding.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance and recorded as a warrant liability. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Stock Subject to Possible Redemption</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its common stock subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Common stock subject to mandatory redemption (if any) is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock feature certain redemption right that is considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet. At June 30, 2021 and December 31, 2020, 18,396,227 and 18,084,699 shares of common stock subject to possible redemption are presented as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 18396227 18084699 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income Taxes </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, “Income Taxes” (“ASC 740”). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of June 30, 2021. The Company’s management determined that the United States is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties for the three-month period ending June 30, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net Income Per Common Share</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. The calculation of diluted loss per common share does not consider the effect of the warrants issued in connection with the (i) IPO, (ii) exercise of over-allotment and (iii) Private Placement since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. The warrants are exercisable to purchase 19,062,500 shares of common stock in the aggregate.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s statement of operations includes a presentation of net income per share for common stock subject to possible redemption in a manner similar to the two-class method. Net income per common share, basic and diluted, for redeemable Common Stock is calculated by dividing the interest income earned on the Trust Account, net of applicable franchise and income taxes, by the weighted average number of redeemable common stock outstanding since original issuance.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 19062500 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reconciliation of Net Income per Common Share</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net income per common share, basic and diluted, for redeemable common stock is calculated by dividing the interest income earned on the Trust Account, by the weighted average number of redeemable common stock outstanding since original issuance. Net income per common stock, basic and diluted, for non-redeemable Common Stock is calculated by dividing the net income, adjusted for income attributable to redeemable common stock, by the weighted average number of non-redeemable common stock outstanding for the periods. Non-redeemable common stock includes the Founder Shares as these shares of common stock do not have any redemption features and do not participate in the income earned on the Trust Account. Accordingly, basic and diluted income per common share is calculated as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months<br/> Ended<br/> June 30, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six Months<br/> Ended<br/> June 30, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Common stock subject to possible redemption</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td>Numerator: Net income allocable to common stock subject to possible redemption</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; text-indent: 20pt">Accretion of interest income on marketable securities held in trust</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,069</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,081</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 20pt">Less: interest available to be withdrawn for payment of taxes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,069</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,081</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 40pt">Net income allocable to Common Stock subject to possible redemption</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 10pt">Denominator: Weighted Average Redeemable Common Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: 20pt">Redeemable Common Stock, Basic and Diluted</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">18,436,292</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">18,263,412</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt; text-indent: 10pt">Basic and Diluted net income per share, Redeemable Common Stock</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.00</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.00</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Non-Redeemable Common Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 10pt">Numerator: Net (Loss) Income minus Redeemable Net Earnings</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 20pt">Net income</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(409,152</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,172,181</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 20pt">Redeemable Net Earnings</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 40pt">Non-Redeemable Net income</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(409,152</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,172,181</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 10pt">Denominator: Weighted Average Non-Redeemable Common Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt; text-indent: 20pt">Basic and diluted weighted average shares outstanding, Common Stock</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">6,719,958</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">6,892,838</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: 10pt">Basic and diluted net income per share, Common Stock</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.06</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.46</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months<br/> Ended<br/> June 30, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six Months<br/> Ended<br/> June 30, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Common stock subject to possible redemption</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td>Numerator: Net income allocable to common stock subject to possible redemption</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; text-indent: 20pt">Accretion of interest income on marketable securities held in trust</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,069</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,081</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 20pt">Less: interest available to be withdrawn for payment of taxes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,069</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,081</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 40pt">Net income allocable to Common Stock subject to possible redemption</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 10pt">Denominator: Weighted Average Redeemable Common Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: 20pt">Redeemable Common Stock, Basic and Diluted</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">18,436,292</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">18,263,412</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt; text-indent: 10pt">Basic and Diluted net income per share, Redeemable Common Stock</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.00</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.00</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Non-Redeemable Common Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 10pt">Numerator: Net (Loss) Income minus Redeemable Net Earnings</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 20pt">Net income</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(409,152</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,172,181</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 20pt">Redeemable Net Earnings</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 40pt">Non-Redeemable Net income</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(409,152</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,172,181</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 10pt">Denominator: Weighted Average Non-Redeemable Common Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt; text-indent: 20pt">Basic and diluted weighted average shares outstanding, Common Stock</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">6,719,958</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">6,892,838</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: 10pt">Basic and diluted net income per share, Common Stock</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.06</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.46</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 5069 10081 -5069 -10081 18436292 18263412 0.00 0.00 -409152 3172181 -409152 3172181 6719958 6892838 -0.06 0.46 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentration of Credit Risk</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 250000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value Measurements</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.4pt; text-align: justify; text-indent: -16.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value of Financial Instruments</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the Company’s assets and liabilities, (excluding the warrant liability) which qualify as financial instruments under the Financial Accounting Standards Board (“FASB”) ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the balance sheet primarily due to their short-term nature.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Derivative Financial Instruments</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. The Company’s derivative instruments are recorded at fair value and re-valued at each reporting date, with changes in the fair value reported in the statements of operations. Derivative assets and liabilities are classified on the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. The Company has determined the warrants are a derivative instrument. As the warrants meet the definition of a derivative the warrants are measured at fair value at issuance and at each reporting date in accordance with ASC 820, Fair Value Measurement, with changes in fair value recognized in the statement of operations in the period of change. In accordance with ASC 825-10 “Financial Instruments”, the Company has concluded that a portion of the transaction costs which directly related to the IPO and the Private Placement, should be allocated to the Warrants based on their relative fair value against total proceeds, and recognized as transaction costs in the statement of operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent Accounting Pronouncements</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 3 — Initial Public Offering</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Public Units</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 28, 2020, the Company sold 17,500,000 Units, at a purchase price of $10.00 per Unit. Each Unit consists of one share of Common Stock, par value $0.0001 per share, one redeemable warrant (the “Public Warrants”) and one right. Each right entitles the holder thereof to receive one-twentieth (1/20) of a share of common stock upon consummation of our initial business combination.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 28, 2020, the Underwriters fully exercised the over-allotment option by purchasing 2,625,000 Units (the “Over-Allotment Units”), generating aggregate of gross proceeds of $26,250,000.</span></p> 17500000 10.00 Each Unit consists of one share of Common Stock, par value $0.0001 per share, one redeemable warrant (the “Public Warrants”) and one right. Each right entitles the holder thereof to receive one-twentieth (1/20) of a share of common stock upon consummation of our initial business combination. 2625000 26250000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4 — Private Placement</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simultaneously with the closing of the IPO, the Sponsor purchased an aggregate of 18,000,000 warrants at a price of $0.50 per warrant ($9,000,000 in the aggregate), each exercisable to purchase one-half of a share common stock at a price of $11.50 per whole share, in a private placement that closed simultaneously with the closing of this offering. A portion of the purchase price of the private placement warrants was added to the proceeds from this offering to be held in the Trust Account</span></p> 18000000 0.50 9000000 11.50 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 5 — Related Party Transactions</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Founder Shares</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the Sponsor paid $25,000, or approximately $0.007 per share, to cover certain offering costs in consideration for 3,593,750 shares of common stock, par value $0.0001 (the “Founder Shares”). On December 3, 2020, the Company declared a share dividend of  0.36 for each outstanding share, resulting in 4,887,500 shares outstanding, and on December 22, 2020 the Company declared a share dividend of  0.03 resulting in 5,031,250 shares which includes an aggregate of up to 656,250 shares that are subject to forfeiture to the extent that the underwriters’ over-allotment option is not exercised in full or in part, and up to an aggregate of 1,006,250 shares of common stock (or 875,000 shares of common stock to the extent that the underwriters’ over-allotment is not exercised, pro rata) that are subject to forfeiture to the extent that rights are exercised upon consummation of an initial business combination. In connection with the underwriters’ fully exercise of their over-allotment option on December 30, 2020 (see Note 3), the 656,250 shares were no longer subject to forfeiture.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The founder shares were placed into an escrow account maintained by Continental Stock Transfer &amp; Trust Company acting as escrow agent. 50% of these shares will not be transferred, assigned, sold or released from escrow until the earlier of (i) 6 months after the date of the consummation of the Company’s initial business combination or (ii) the date on which the closing price of the Company’s shares of common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing after its initial business combination and the remaining 50% of the founder shares will not be transferred, assigned, sold or released from escrow until 6 months after the date of the consummation of the Company’s initial business combination, or earlier, in either case, if, subsequent to its initial business combination, the Company consummates a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of its stockholders having the right to exchange their shares of common stock for cash, securities or other property.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the escrow period, the holders of these shares will not be able to sell or transfer their securities except (1) to any persons (including their affiliates and stockholders) participating in the private placement of the private warrants, officers, directors, stockholders, employees and members of the Company’s sponsor and its affiliates, (2) amongst initial stockholders or their respective affiliates, or to the Company’s officers, directors, advisors and employees, (3) if a holder is an entity, as a distribution to its, partners, stockholders or members upon its liquidation, (4) by bona fide gift to a member of the holder’s immediate family or to a trust, the beneficiary of which is a holder or a member of a holder’s immediate family, for estate planning purposes, (5) by virtue of the laws of descent and distribution upon death, (6) pursuant to a qualified domestic relations order, (7) by certain pledges to secure obligations incurred in connection with purchases of the Company’s securities, (8) by private sales at prices no greater than the price at which the shares were originally purchased or (9) for the cancellation of up to 656,250 shares of common stock subject to forfeiture to the extent that the underwriters’ over-allotment is not exercised in full or in part or in connection with the consummation of the Company’s initial business combination, in each case (except for clause 9 or with the Company’s prior consent) where the transferee agrees to the terms of the escrow agreement and the insider letter.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Promissory Note — Related Party</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Sponsor agreed to loan the Company an aggregate of up to $500,000 to cover expenses related to the Initial Public Offering pursuant to a promissory note (the “Note”). This loan is non-interest bearing and payable on the earlier of March 31, 2021 or the completion of the Initial Public Offering. <span>On January 13, 2021, the Company paid the $228,758 balance on the note from the proceeds of the IPO. As of </span> June 30, 2021<span>, the Company had no balance under the Note.</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Working Capital Loans</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). Each loan would be evidenced by a promissory note. The notes would be repaid upon consummation of the Company’s initial business combination, without interest. As of June 30, 2021 and December 31, 2020, the Company had no borrowings under the Working Capital Loans.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Administrative Service Fee</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing on the date of the final prospectus, the Company has agreed to pay the Sponsor a total of $20,000 per month for office space, utilities and secretarial support. Upon completion of the initial Business Combination or the Company’s liquidation, the Company will cease paying these monthly fees. The Company has incurred $120,000 and accrued $110,000 of administrative service fees for the six months ended June 30, 2021 and any unpaid amounts are accrued in Due to related party.</span></p> 25000 0.007 3593750 0.0001 0.36 4887500 0.03 5031250 656250 1006250 875000 656250 50% of these shares will not be transferred, assigned, sold or released from escrow until the earlier of (i) 6 months after the date of the consummation of the Company’s initial business combination or (ii) the date on which the closing price of the Company’s shares of common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing after its initial business combination and the remaining 50% of the founder shares will not be transferred, assigned, sold or released from escrow until 6 months after the date of the consummation of the Company’s initial business combination, or earlier, in either case, if, subsequent to its initial business combination, the Company consummates a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of its stockholders having the right to exchange their shares of common stock for cash, securities or other property. 656250 500000 228758 20000 120000 110000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 6 — Commitments and Contingencies</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Underwriting Agreement</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The underwriters were entitled to deferred underwriting fee of 3.5% <span>of the gross proceeds of the IPO</span>, or $7,043,750 in the aggregate. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registration Rights</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The holders of the Company’s insider shares issued and outstanding on the date of this prospectus, as well as the holders of the private warrants (and underlying securities) will be entitled to registration rights pursuant to an agreement to be signed prior to or on the effective date of this offering. The holders of a majority of these securities are entitled to make up to two demands that the Company registers such securities. The holders of the majority of the insider shares can elect to exercise these registration rights at any time commencing three months prior to the date on which these shares of common stock are to be released from escrow. The holders of a majority of the private warrants (and underlying securities) can elect to exercise these registration rights at any time after the Company consummates a business combination. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the Company’s consummation of a business combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.</span></p> The underwriters were entitled to deferred underwriting fee of 3.5% of the gross proceeds of the IPO, or $7,043,750 in the aggregate. <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 7 — Stockholders’ Equity</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred Stock</i></b> — The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 and with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of June 30, 2021 and December 31, 2020, there was no preferred stock issued or outstanding.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common Stock </i></b>— The Company is authorized to issue 60,000,000 shares of common stock with a par value of $0.0001 per share. Holders are entitled to one vote for each share of common stock. As of June 30, 2021, 2021 and December 31, 2020, there were 6,760,023 and 7,071,551 shares of common stock issued and outstanding, excluding 18,396,227 and 18,084,699 shares of common stock subject to possible redemption, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rights —</b>Except in cases where the Company is not the surviving company in a business combination, each holder of a right will automatically receive one-twentieth (1/20) of a share of common stock upon consummation of the initial business combination. In the event the Company will not be the surviving company upon completion of the initial business combination, each holder of a right will be required to affirmatively convert his, her or its rights in order to receive the one-twentieth (1/20) of a share underlying each right upon consummation of the business combination. The Company will not issue fractional shares in connection with an exchange of rights. Fractional shares will either be rounded down to the nearest whole share or otherwise addressed in accordance with the applicable provisions of the Delaware General Corporation Law. As a result, holders must hold rights in multiples of 20 in order to receive shares for all rights upon closing of a business combination. If the Company is unable to complete an initial business combination within the required time period and the Company redeems the public shares for the funds held in the trust account, holders of rights will not receive any of such funds for their rights and the rights will expire worthless.</span></p> 1000000 0.0001 60000000 0.0001 Holders are entitled to one vote for each share of common stock. 6760023 7071551 18396227 18084699 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 8 — Warrants</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Public Warrants</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Each warrant entitles the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $11.50 per whole share, subject to adjustment as described in this prospectus. Each right entitles the holder thereof to receive one-twentieth (1/20) of a share of common stock upon consummation of our initial business combination. Pursuant to the warrant agreement, a warrant holder may exercise its public warrants only for a whole number of shares. This means that only an even number of public warrants may be exercised at any given time by a warrant holder.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">T<span>he Company may call the warrants for redemption (except the Private Warrants)</span>:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in whole and not in part;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at a price of $0.01 per warrant;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon not less than 30 days’ prior written notice of redemption (the “30-day redemption period”) to each warrant holder; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if and only if, there is a current registration statement in effect with respect to the shares of common stock underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Company calls the warrants for redemption as described above, its management will have the option to require all holders that wish to exercise warrants to do so on a “cashless basis.” In such event, each holder would pay the exercise price by surrendering the warrants for that number of shares of common stock equal to the quotient obtained by dividing (x) the product of the number of shares of common stock underlying the warrants, multiplied by the difference between the exercise price of the warrants and the “fair market value” (defined below) by (y) the fair market value. The “fair market value” shall mean the average reported last sale price of the Company’s common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. Whether the Company will exercise our option to require all holders to exercise their warrants on a “cashless basis” will depend on a variety of factors including the price of our common shares at the time the warrants are called for redemption, its cash needs at such time and concerns regarding dilutive share issuances. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If (x) the Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of its initial business combination at an issue price or effective issue price of less than $9.50 per share of common stock (with such issue price or effective issue price to be determined in good faith by its board of directors, and in the case of any such issuance to its sponsor, initial stockholders or their affiliates, without taking into account any founders’ shares held by them prior to such issuance), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of our initial business combination on the date of the consummation of our initial business combination (net of redemptions), and (z) the Market Value is below $9.50 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of (i) the Market Value or (ii) the price at which the Company issues the additional shares of common stock or equity-linked securities and the $16.50 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to 165% of the Market Value. The warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price, by certified or official bank check payable to the Company, for the number of warrants being exercised. The warrant holders do not have the rights or privileges of holders of shares of common stock and any voting rights until they exercise their warrants and receive shares of common stock. After the issuance of shares of common stock upon exercise of the warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by stockholders.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Private Warrants</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The private warrants are identical to the warrants sold as part of the public units in this offering except that the private warrants will be non-redeemable and may be exercised on a cashless basis, in each case so long as they continue to be held by the initial purchasers or their permitted transferees. Additionally, if public units or shares of common stock are purchased by any of the directors, officers or initial stockholders, they will be entitled to funds from the trust account to the same extent as any public stockholder upon our liquidation but will not have redemption rights related thereto.</span></p> Each warrant entitles the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $11.50 per whole share, subject to adjustment as described in this prospectus. Each right entitles the holder thereof to receive one-twentieth (1/20) of a share of common stock upon consummation of our initial business combination. Pursuant to the warrant agreement, a warrant holder may exercise its public warrants only for a whole number of shares. This means that only an even number of public warrants may be exercised at any given time by a warrant holder. ●in whole and not in part;    ●at a price of $0.01 per warrant;    ●upon not less than 30 days’ prior written notice of redemption (the “30-day redemption period”) to each warrant holder; and    ●if and only if, there is a current registration statement in effect with respect to the shares of common stock underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption. If (x) the Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of its initial business combination at an issue price or effective issue price of less than $9.50 per share of common stock (with such issue price or effective issue price to be determined in good faith by its board of directors, and in the case of any such issuance to its sponsor, initial stockholders or their affiliates, without taking into account any founders’ shares held by them prior to such issuance), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of our initial business combination on the date of the consummation of our initial business combination (net of redemptions), and (z) the Market Value is below $9.50 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of (i) the Market Value or (ii) the price at which the Company issues the additional shares of common stock or equity-linked securities and the $16.50 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to 165% of the Market Value. The warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price, by certified or official bank check payable to the Company, for the number of warrants being exercised. The warrant holders do not have the rights or privileges of holders of shares of common stock and any voting rights until they exercise their warrants and receive shares of common stock. After the issuance of shares of common stock upon exercise of the warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by stockholders.  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 9 — Fair Value Measurements</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis at June 30, 2021, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Assets:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Mutual Funds held in Trust Account</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">203,272,741</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">203,272,741</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">—</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">—</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">203,272,741</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">203,272,741</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Private Warrant Liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,631,815</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,631,815</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,631,815</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,631,815</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Warrants are accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liabilities on the Condensed Balance Sheet. The warrant liabilities were measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrant liabilities in the Condensed Statement of Operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company established the initial fair value of the Private Warrants on December 28, 2020, the date of the Company’s Initial Public Offering, and revalued on December 31, 2020 and on June 30, 2021 , using a Monte Carlo simulation model. The Warrants were classified as Level 3 at the initial measurement date due to the use of unobservable inputs.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The key inputs into the Monte Carlo simulation as of December 31, 2020 and June 30, 2021 were as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold">Inputs</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Risk-free interest rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">0.52</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">0.98</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected term remaining (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.63</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24.2</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13.4</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td>Stock price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">9.625</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">9.900</td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The change in the fair value of the Private Warrant liability for the period ended June 30, 2021 is summarized as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Fair value at December 31, 2020</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,763,361</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Change in fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,131,546</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Fair Value at June 30, 2021</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,631,815</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Assets:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Mutual Funds held in Trust Account</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">203,272,741</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">203,272,741</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">—</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">—</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">203,272,741</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">203,272,741</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Private Warrant Liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,631,815</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,631,815</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,631,815</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,631,815</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 203272741 203272741 203272741 203272741 6631815 6631815 6631815 6631815 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold">Inputs</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Risk-free interest rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">0.52</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">0.98</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected term remaining (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.63</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24.2</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13.4</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td>Stock price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">9.625</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">9.900</td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.0052 0.0098 P6Y1M13D P5Y7M17D 0.242 0.134 9.625 9.900 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Fair value at December 31, 2020</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,763,361</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Change in fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,131,546</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Fair Value at June 30, 2021</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,631,815</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 10763361 -4131546 6631815 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 10 — Subsequent Events</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.</span></p> false --12-31 Q2 0001823857 XML 11 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document And Entity Information - shares
 6 Months Ended
Jun. 30, 2021
Aug. 16, 2021
Document Information Line Items    
Entity Registrant Name VIVEON HEALTH ACQUISITION CORP.  
Trading Symbol VHAQ  
Document Type 10-Q  
Current Fiscal Year End Date --12-31  
Entity Common Stock, Shares Outstanding   25,156,250
Amendment Flag false  
Entity Central Index Key 0001823857  
Entity Current Reporting Status Yes  
Entity Filer Category Non-accelerated Filer  
Document Period End Date Jun. 30, 2021  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q2  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Shell Company true  
Entity Ex Transition Period false  
Document Quarterly Report true  
Document Transition Report false  
Entity File Number 001-39827  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 85-2788202  
Entity Address, Address Line One c/o Gibson, Deal & Fletcher, PC Spalding Exchange  
Entity Address, Address Line Two 3953 Holcomb Bridge Road  
Entity Address, Address Line Three Suite 200  
Entity Address, City or Town Norcross  
Entity Address, State or Province GA  
Entity Address, Postal Zip Code 30092  
City Area Code (404)  
Local Phone Number -861-5393  
Title of 12(b) Security Common Stock  
Security Exchange Name NYSE  
Entity Interactive Data Current Yes  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Balance Sheets - USD ($)
Jun. 30, 2021
Dec. 31, 2020
Assets:    
Cash and cash equivalents $ 1,056,622 $ 3,096,956
Prepaid Expenses 339,671 660,695
Total current assets 1,396,293 3,757,651
Investment held in Trust Account 203,272,741 203,262,660
Total Assets 204,669,034 207,020,311
Current liabilities    
Accrued costs and expenses 75,767 958,292
Other payable – related party 364,880
Promissory note – related party 228,758
Due to related party 115,806 5,806
Total current liabilities 191,573 1,557,736
Deferred underwriting fee 7,043,750 7,043,750
Warrant liability 6,631,815 10,763,361
Total liabilities 13,867,138 19,364,847
Commitments and Contingencies
Common Stock subject to possible redemption, 18,396,227 and 18,084,699 shares at redemption value at June 30, 2021 and December 31, 2020, respectively 185,801,895 182,655,456
Stockholders’ Equity:    
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding
Common stock, $0.0001 par value; 60,000,000 shares authorized; 6,760,023 and 7,071,551 shares issued and outstanding (excluding 18,396,227 and 18,084,699 shares subject to possible redemption) at June 30, 2021 and December 31, 2020, respectively 676 707
Additional paid-in capital 3,641,297 6,813,454
Retained Earnings (Accumulated deficit) 1,358,028 (1,814,153)
Total stockholders’ Equity 5,000,001 5,000,008
Total Liabilities and Stockholders’ Equity $ 204,669,034 $ 207,020,311
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Balance Sheets (Parentheticals) - $ / shares
Jun. 30, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Common stock subject to possible redemption shares 18,396,227 18,084,699
Preferred stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized 60,000,000 60,000,000
Common stock, shares issued 6,760,023 7,071,551
Common stock, shares outstanding 6,760,023 7,071,551
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2021
Income Statement [Abstract]    
Formation and operating costs $ 648,124 $ 969,557
Loss from Operations (648,124) (969,557)
Other income:    
Interest earned on investments held in Trust Account 5,069 10,081
Interest earned on bank account 30 111
Change in fair value of warrant liability 233,873 4,131,546
Total other income 238,972 4,141,738
Net (loss) income $ (409,152) $ 3,172,181
Basic and diluted, weighted average shares outstanding – non-redeemable common stock (in Shares) 6,719,958 6,892,838
Basic and diluted net (loss) income per share (in Dollars per share) $ (0.06) $ 0.46
Basic and diluted weighted average shares outstanding – redeemable common stock (in Shares) 18,436,292 18,263,412
Basic and diluted net income per share (in Dollars per share) $ 0.00 $ 0.00
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Statement of Changes in Stockholders’ Equity (Unaudited) - USD ($)
Common Stock
Additional Paid-in Capital
Retained Earnings/ (Accumulated Deficit)
Total
Balance at Dec. 31, 2020 $ 707 $ 6,813,454 $ (1,814,153) $ 5,000,008
Balance (in Shares) at Dec. 31, 2020 7,071,551      
Deferred offering costs (25,749) (25,749)
Net income 3,172,181 3,172,181
Change in common stock subject to possible redemption $ (31) (3,146,408) (3,146,439)
Change in common stock subject to possible redemption (in Shares) (311,528)      
Balance at Jun. 30, 2021 $ 676 3,641,297 1,358,028 5,000,001
Balance (in Shares) at Jun. 30, 2021 6,760,023      
Balance at Mar. 31, 2021 $ 672 3,232,152 1,767,180 5,000,004
Balance (in Shares) at Mar. 31, 2021 6,719,513      
Net income (409,152) (409,152)
Change in common stock subject to possible redemption $ 4 409,145 409,149
Change in common stock subject to possible redemption (in Shares) 40,510      
Balance at Jun. 30, 2021 $ 676 $ 3,641,297 $ 1,358,028 $ 5,000,001
Balance (in Shares) at Jun. 30, 2021 6,760,023      
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Statement of Cash Flows (Unaudited)
 6 Months Ended
Jun. 30, 2021
USD ($)
Cash flows from operating activities:  
Net Income $ 3,172,181
Adjustments to reconcile net income to net cash used in operating activities:  
Interest earned on investments held in Trust Account (10,081)
Change in fair value of warrant liability (4,131,546)
Changes in operating assets and liabilities:  
Prepaid assets 321,024
Accrued costs and expenses (908,274)
Due to related party 110,000
Net cash used in operating activities (1,446,696)
Cash Flows from Financing Activities:  
Payment of promissory note (228,758)
Payment of other payable – related party (364,880)
Net cash used in financing activities (593,638)
Net change in cash and cash equivalents (2,040,334)
Cash and cash equivalents, beginning of period 3,096,956
Cash and cash equivalents, end of the period 1,056,622
Supplemental disclosure of cash flow information:  
Change in value of common stock subject to possible redemption $ 3,146,439
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Organization and Business Operation
 6 Months Ended
Jun. 30, 2021
Accounting Policies [Abstract]  
Organization and Business Operation

Note 1 — Organization and Business Operations

 

Viveon Health Acquisition Corp. (the “Company”) is a newly organized blank check company incorporated as a Delaware company on August 7, 2020. The Company was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities (“Business Combination”).

 

We have neither engaged in any operations nor generated any revenues to date. Our only activities from August 7, 2020 (inception) through June 30, 2021 were organizational activities, those necessary to prepare for the Initial Public Offering, described below, and, after our Initial Public Offering, identifying a target company for a Business Combination. We do not expect to generate any operating revenues until after the completion of our Business Combination. We generate non-operating income in the form of interest income on marketable securities held after the Initial Public Offering. We incur expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses. The Company’s sponsor is Viveon Health LLC, a Delaware limited liability company (the “Sponsor”).

 

Upon closing of the IPO and the sale of the Over-Allotment Units, $203,262,500 (approximately $10.10 per Unit) from net offering proceeds of the sale of the Units in the IPO and the sale of the Private Warrants was placed in a trust account (the “Trust Account”) and invested in U.S. government securities, with a maturity of 180 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act, which invest only in direct U.S. government treasury obligations. Except with respect to interest earned on the funds held in the Trust Account that may be released to the Company to pay its tax obligations, the proceeds from the IPO will not be released from the Trust Account until the earliest to occur of (1) the completion of the Company’s initial Business Combination within 15 months and (2) the Company’s redemption of 100% of the outstanding public shares if the Company has not completed a business combination in the required time period.

 

The Company’s management has broad discretion with respect to the specific application of the net proceeds of the IPO, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the assets held in the Trust Account (as defined below) (net of amounts disbursed to management for working capital purposes, if permitted, and excluding the amount of any deferred underwriting commissions) at the time of the agreement to enter into the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires an interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act 1940, as amended (the “Investment Company Act”).

 

In connection with any proposed initial Business Combination, the Company will either (1) seek stockholder approval of such initial Business Combination at a meeting called for such purpose at which public stockholders may seek to convert their public shares, regardless of whether they vote for or against the proposed business combination, into their pro rata share of the aggregate amount then on deposit in the trust account (net of taxes payable) or (2) provide its public stockholders with the opportunity to sell their public shares to the Company by means of a tender offer (and thereby avoid the need for a stockholder vote) for an amount equal to their pro rata share of the aggregate amount then on deposit in the trust account (net of taxes payable), in each case subject to the limitations described herein.

  

If the Company determines to engage in a tender offer, such tender offer will be structured so that each public stockholder may tender any or all of his, her or its public shares rather than some pro rata portion of his, her or its shares. If enough stockholders tender their shares so that the Company is unable to satisfy any applicable closing condition set forth in the definitive agreement related to its initial Business Combination, or the Company is unable to maintain net tangible assets of at least $5,000,001, the Company will not consummate such initial Business Combination. The decision as to whether it will seek stockholder approval of a proposed business combination or will allow stockholders to sell their shares to the Company in a tender offer will be made by the Company based on a variety of factors such as the timing of the transaction or whether the terms of the transaction would otherwise require us to seek stockholder approval.

 

If the Company provides stockholders with the opportunity to sell their shares to it by means of a tender offer, it will file tender offer documents with the SEC which will contain substantially the same financial and other information about the initial Business Combination as is required under the SEC’s proxy rules. If the Company seeks stockholder approval of its initial Business Combination, the Company will consummate the business combination only if a majority of the outstanding shares of common stock present in person or by proxy at a meeting of the Company are voted in favor of the business combination.

 

Notwithstanding the foregoing redemption rights, if the Company seeks stockholder approval of its initial Business Combination and the Company does not conduct redemptions in connection with its initial Business Combination pursuant to the tender offer rules, the Amended and Restated Certificate of Incorporation will provide that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Exchange Act), will be restricted from redeeming its shares with respect to more than an aggregate of 20% of the shares sold in this offering, without the Company’s prior consent. The Company’s sponsor, officers and directors (the “initial stockholders”) have agreed not to propose any amendment to the Amended and Restated Certificate of Incorporation (a) that would modify the substance or timing of the Company’s obligation to provide for the redemption of its public shares in connection with an initial Business Combination or to redeem 100% of its public shares if the Company does not complete its initial Business Combination within 15 months from the closing of the IPO (the “Combination Period”) or (b) with respect to any other material provisions relating to stockholders’ rights or pre-initial Business Combination activity, unless the Company provide its public stockholders with the opportunity to redeem their shares of common stock in conjunction with any such amendment.

 

If the Company is unable to complete its initial Business Combination within the Combination Period, the Company will: (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than five business days thereafter, redeem 100% of the outstanding public shares (including any public units in this offering or any public units or shares that its initial stockholders or their affiliates purchased in this offering or later acquired in the open market or in private transactions), which will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably practicable following such redemption, subject to the approval of the Company’s remaining holders of common stock and its board of directors, proceed to commence a voluntary liquidation and thereby a formal dissolution of the Company, subject (in the case of (ii) and (iii) above) to its obligations to provide for claims of creditors and the requirements of applicable law.

 

The Company’s initial stockholders agreed to waive their rights to liquidating distributions from the Trust Account with respect to any founder shares held by them if the Company fails to complete its initial Business Combination within the Combination Period. However, if the initial stockholders acquire public shares in or after the IPO, they will be entitled to liquidating distributions from the Trust Account with respect to such public shares if the Company fails.

 

Risks and Uncertainties 

 

Management is currently continuing to evaluate the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Liquidity and Capital Resources

 

As of June 30, 2021, the Company had $1,056,622 of cash and cash equivalents held outside the Trust Account available for working capital needs. All remaining cash held in the Trust Account is generally unavailable for the Company’s use, prior to an initial business combination, and is restricted for use either in a Business Combination or to redeem common stock. As of June 30, 2021 and December 31, 2020, none of the amount in the Trust Account was available to be withdrawn as described above.

  

The Company anticipates that the $1,056,622 outside of the Trust Account as of June 30, 2021, will be sufficient to allow the Company to operate for at least the next 12 months from the issuance of the financial statements, assuming that a Business Combination is not consummated during that time. Until consummation of its Business Combination, the Company will be using the funds not held in the Trust Account, and any additional Working Capital Loans (as defined in Note 5) from the initial stockholders, the Company’s officers and directors, or their respective affiliates (which is described in Note 5), for identifying and evaluating prospective acquisition candidates, performing business due diligence on prospective target businesses, traveling to and from the offices, plants or similar locations of prospective target businesses, reviewing corporate documents and material agreements of prospective target businesses, selecting the target business to acquire and structuring, negotiating and consummating the Business Combination.

 

Emerging Growth Company

 

The Company is an “emerging growth company”, as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

 

In addition, Section 107 of the JOBS Act also provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company intends to take advantage of the benefits of this extended transition period.
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Significant Accounting Policies
 6 Months Ended
Jun. 30, 2021
Accounting Policies [Abstract]  
Significant Accounting Policies

Note 2 — Significant Accounting Policies

 

Basis of Presentation 

 

The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented.

  

The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K/A for the year ended December 31, 2020 as filed with the SEC on July 2, 2021, which contains the audited financial statements and notes thereto. The interim results for the six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any future interim periods.

 

Use of Estimates

 

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The cash equivalents in the amount of $950,419 and $3,092,771, were held in money market funds as of June 30, 2021 and December 31, 2020, respectively.

 

Marketable Securities Held in Trust Account

 

At June 30, 2021 and December 31, 2020, substantially all of the assets held in the Trust Account were held in mutual funds which invest in U.S. Treasury securities. The mutual fund assets in the amount of $203,272,741 and $203,262,660 were held in the Trust Account as of June 30, 2021 and December 31, 2020, respectively.

 

Warrants

 

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date for Private Warrants while the warrants are outstanding.

 

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance and recorded as a warrant liability. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations.

 

Common Stock Subject to Possible Redemption

 

The Company accounts for its common stock subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Common stock subject to mandatory redemption (if any) is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock feature certain redemption right that is considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet. At June 30, 2021 and December 31, 2020, 18,396,227 and 18,084,699 shares of common stock subject to possible redemption are presented as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet.

 

Income Taxes 

 

The Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, “Income Taxes” (“ASC 740”). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

 

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of June 30, 2021. The Company’s management determined that the United States is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties for the three-month period ending June 30, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.

 

Net Income Per Common Share

 

Net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. The calculation of diluted loss per common share does not consider the effect of the warrants issued in connection with the (i) IPO, (ii) exercise of over-allotment and (iii) Private Placement since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. The warrants are exercisable to purchase 19,062,500 shares of common stock in the aggregate.

 

The Company’s statement of operations includes a presentation of net income per share for common stock subject to possible redemption in a manner similar to the two-class method. Net income per common share, basic and diluted, for redeemable Common Stock is calculated by dividing the interest income earned on the Trust Account, net of applicable franchise and income taxes, by the weighted average number of redeemable common stock outstanding since original issuance.

 

Reconciliation of Net Income per Common Share

 

Net income per common share, basic and diluted, for redeemable common stock is calculated by dividing the interest income earned on the Trust Account, by the weighted average number of redeemable common stock outstanding since original issuance. Net income per common stock, basic and diluted, for non-redeemable Common Stock is calculated by dividing the net income, adjusted for income attributable to redeemable common stock, by the weighted average number of non-redeemable common stock outstanding for the periods. Non-redeemable common stock includes the Founder Shares as these shares of common stock do not have any redemption features and do not participate in the income earned on the Trust Account. Accordingly, basic and diluted income per common share is calculated as follows:

 

   Three Months
Ended
June 30,
2021		   Six Months
Ended
June 30,
2021		 
Common stock subject to possible redemption        
Numerator: Net income allocable to common stock subject to possible redemption        
Accretion of interest income on marketable securities held in trust  $5,069   $10,081 
Less: interest available to be withdrawn for payment of taxes   (5,069)   (10,081)
Net income allocable to Common Stock subject to possible redemption  $
—
   $— 
Denominator: Weighted Average Redeemable Common Stock          
Redeemable Common Stock, Basic and Diluted   18,436,292    18,263,412 
Basic and Diluted net income per share, Redeemable Common Stock  $0.00   $0.00 
           
Non-Redeemable Common Stock          
Numerator: Net (Loss) Income minus Redeemable Net Earnings          
Net income  $(409,152)  $3,172,181 
Redeemable Net Earnings   
—
    — 
Non-Redeemable Net income  $(409,152)  $3,172,181 
Denominator: Weighted Average Non-Redeemable Common Stock          
Basic and diluted weighted average shares outstanding, Common Stock   6,719,958    6,892,838 
Basic and diluted net income per share, Common Stock  $(0.06)  $0.46 

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

 

Fair Value Measurements

 

Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:

 

  ● Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;

 

  ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

 

  ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

Fair Value of Financial Instruments

 

The fair value of the Company’s assets and liabilities, (excluding the warrant liability) which qualify as financial instruments under the Financial Accounting Standards Board (“FASB”) ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the balance sheet primarily due to their short-term nature.

 

Derivative Financial Instruments

 

The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. The Company’s derivative instruments are recorded at fair value and re-valued at each reporting date, with changes in the fair value reported in the statements of operations. Derivative assets and liabilities are classified on the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. The Company has determined the warrants are a derivative instrument. As the warrants meet the definition of a derivative the warrants are measured at fair value at issuance and at each reporting date in accordance with ASC 820, Fair Value Measurement, with changes in fair value recognized in the statement of operations in the period of change. In accordance with ASC 825-10 “Financial Instruments”, the Company has concluded that a portion of the transaction costs which directly related to the IPO and the Private Placement, should be allocated to the Warrants based on their relative fair value against total proceeds, and recognized as transaction costs in the statement of operations.

 

Recent Accounting Pronouncements

 

Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Initial Public Offering
 6 Months Ended
Jun. 30, 2021
Initial Public Offering [Abstract]  
Initial Public Offering

Note 3 — Initial Public Offering

 

Public Units

 

On December 28, 2020, the Company sold 17,500,000 Units, at a purchase price of $10.00 per Unit. Each Unit consists of one share of Common Stock, par value $0.0001 per share, one redeemable warrant (the “Public Warrants”) and one right. Each right entitles the holder thereof to receive one-twentieth (1/20) of a share of common stock upon consummation of our initial business combination.

 

On December 28, 2020, the Underwriters fully exercised the over-allotment option by purchasing 2,625,000 Units (the “Over-Allotment Units”), generating aggregate of gross proceeds of $26,250,000.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Private Placement
 6 Months Ended
Jun. 30, 2021
Private Placement Disclosure [Abstract]  
Private Placement

Note 4 — Private Placement

 

Simultaneously with the closing of the IPO, the Sponsor purchased an aggregate of 18,000,000 warrants at a price of $0.50 per warrant ($9,000,000 in the aggregate), each exercisable to purchase one-half of a share common stock at a price of $11.50 per whole share, in a private placement that closed simultaneously with the closing of this offering. A portion of the purchase price of the private placement warrants was added to the proceeds from this offering to be held in the Trust Account
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Related Party Transactions
 6 Months Ended
Jun. 30, 2021
Related Party Transactions [Abstract]  
Related Party Transactions

Note 5 — Related Party Transactions

 

Founder Shares

 

In August 2020, the Sponsor paid $25,000, or approximately $0.007 per share, to cover certain offering costs in consideration for 3,593,750 shares of common stock, par value $0.0001 (the “Founder Shares”). On December 3, 2020, the Company declared a share dividend of  0.36 for each outstanding share, resulting in 4,887,500 shares outstanding, and on December 22, 2020 the Company declared a share dividend of  0.03 resulting in 5,031,250 shares which includes an aggregate of up to 656,250 shares that are subject to forfeiture to the extent that the underwriters’ over-allotment option is not exercised in full or in part, and up to an aggregate of 1,006,250 shares of common stock (or 875,000 shares of common stock to the extent that the underwriters’ over-allotment is not exercised, pro rata) that are subject to forfeiture to the extent that rights are exercised upon consummation of an initial business combination. In connection with the underwriters’ fully exercise of their over-allotment option on December 30, 2020 (see Note 3), the 656,250 shares were no longer subject to forfeiture.

 

The founder shares were placed into an escrow account maintained by Continental Stock Transfer & Trust Company acting as escrow agent. 50% of these shares will not be transferred, assigned, sold or released from escrow until the earlier of (i) 6 months after the date of the consummation of the Company’s initial business combination or (ii) the date on which the closing price of the Company’s shares of common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing after its initial business combination and the remaining 50% of the founder shares will not be transferred, assigned, sold or released from escrow until 6 months after the date of the consummation of the Company’s initial business combination, or earlier, in either case, if, subsequent to its initial business combination, the Company consummates a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of its stockholders having the right to exchange their shares of common stock for cash, securities or other property.

 

During the escrow period, the holders of these shares will not be able to sell or transfer their securities except (1) to any persons (including their affiliates and stockholders) participating in the private placement of the private warrants, officers, directors, stockholders, employees and members of the Company’s sponsor and its affiliates, (2) amongst initial stockholders or their respective affiliates, or to the Company’s officers, directors, advisors and employees, (3) if a holder is an entity, as a distribution to its, partners, stockholders or members upon its liquidation, (4) by bona fide gift to a member of the holder’s immediate family or to a trust, the beneficiary of which is a holder or a member of a holder’s immediate family, for estate planning purposes, (5) by virtue of the laws of descent and distribution upon death, (6) pursuant to a qualified domestic relations order, (7) by certain pledges to secure obligations incurred in connection with purchases of the Company’s securities, (8) by private sales at prices no greater than the price at which the shares were originally purchased or (9) for the cancellation of up to 656,250 shares of common stock subject to forfeiture to the extent that the underwriters’ over-allotment is not exercised in full or in part or in connection with the consummation of the Company’s initial business combination, in each case (except for clause 9 or with the Company’s prior consent) where the transferee agrees to the terms of the escrow agreement and the insider letter.

 

Promissory Note — Related Party

 

The Sponsor agreed to loan the Company an aggregate of up to $500,000 to cover expenses related to the Initial Public Offering pursuant to a promissory note (the “Note”). This loan is non-interest bearing and payable on the earlier of March 31, 2021 or the completion of the Initial Public Offering. On January 13, 2021, the Company paid the $228,758 balance on the note from the proceeds of the IPO. As of June 30, 2021, the Company had no balance under the Note.

 

Working Capital Loans

 

In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). Each loan would be evidenced by a promissory note. The notes would be repaid upon consummation of the Company’s initial business combination, without interest. As of June 30, 2021 and December 31, 2020, the Company had no borrowings under the Working Capital Loans.

 

Administrative Service Fee

 

Commencing on the date of the final prospectus, the Company has agreed to pay the Sponsor a total of $20,000 per month for office space, utilities and secretarial support. Upon completion of the initial Business Combination or the Company’s liquidation, the Company will cease paying these monthly fees. The Company has incurred $120,000 and accrued $110,000 of administrative service fees for the six months ended June 30, 2021 and any unpaid amounts are accrued in Due to related party.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies
 6 Months Ended
Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 6 — Commitments and Contingencies

 

Underwriting Agreement

 

The underwriters were entitled to deferred underwriting fee of 3.5% of the gross proceeds of the IPO, or $7,043,750 in the aggregate. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.

 

Registration Rights

 

The holders of the Company’s insider shares issued and outstanding on the date of this prospectus, as well as the holders of the private warrants (and underlying securities) will be entitled to registration rights pursuant to an agreement to be signed prior to or on the effective date of this offering. The holders of a majority of these securities are entitled to make up to two demands that the Company registers such securities. The holders of the majority of the insider shares can elect to exercise these registration rights at any time commencing three months prior to the date on which these shares of common stock are to be released from escrow. The holders of a majority of the private warrants (and underlying securities) can elect to exercise these registration rights at any time after the Company consummates a business combination. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the Company’s consummation of a business combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholders’ Equity
 6 Months Ended
Jun. 30, 2021
Stockholders' Equity Note [Abstract]  
Stockholders’ Equity

Note 7 — Stockholders’ Equity

 

Preferred Stock — The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 and with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of June 30, 2021 and December 31, 2020, there was no preferred stock issued or outstanding.

 

Common Stock — The Company is authorized to issue 60,000,000 shares of common stock with a par value of $0.0001 per share. Holders are entitled to one vote for each share of common stock. As of June 30, 2021, 2021 and December 31, 2020, there were 6,760,023 and 7,071,551 shares of common stock issued and outstanding, excluding 18,396,227 and 18,084,699 shares of common stock subject to possible redemption, respectively.

 

Rights —Except in cases where the Company is not the surviving company in a business combination, each holder of a right will automatically receive one-twentieth (1/20) of a share of common stock upon consummation of the initial business combination. In the event the Company will not be the surviving company upon completion of the initial business combination, each holder of a right will be required to affirmatively convert his, her or its rights in order to receive the one-twentieth (1/20) of a share underlying each right upon consummation of the business combination. The Company will not issue fractional shares in connection with an exchange of rights. Fractional shares will either be rounded down to the nearest whole share or otherwise addressed in accordance with the applicable provisions of the Delaware General Corporation Law. As a result, holders must hold rights in multiples of 20 in order to receive shares for all rights upon closing of a business combination. If the Company is unable to complete an initial business combination within the required time period and the Company redeems the public shares for the funds held in the trust account, holders of rights will not receive any of such funds for their rights and the rights will expire worthless.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Warrants
 6 Months Ended
Jun. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Warrants

Note 8 — Warrants

 

Public Warrants

 

 Each warrant entitles the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $11.50 per whole share, subject to adjustment as described in this prospectus. Each right entitles the holder thereof to receive one-twentieth (1/20) of a share of common stock upon consummation of our initial business combination. Pursuant to the warrant agreement, a warrant holder may exercise its public warrants only for a whole number of shares. This means that only an even number of public warrants may be exercised at any given time by a warrant holder.

 

The Company may call the warrants for redemption (except the Private Warrants):

 

  ● in whole and not in part;
     
  ● at a price of $0.01 per warrant;
     
  ● upon not less than 30 days’ prior written notice of redemption (the “30-day redemption period”) to each warrant holder; and
     
  ● if and only if, there is a current registration statement in effect with respect to the shares of common stock underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption.

 

If the Company calls the warrants for redemption as described above, its management will have the option to require all holders that wish to exercise warrants to do so on a “cashless basis.” In such event, each holder would pay the exercise price by surrendering the warrants for that number of shares of common stock equal to the quotient obtained by dividing (x) the product of the number of shares of common stock underlying the warrants, multiplied by the difference between the exercise price of the warrants and the “fair market value” (defined below) by (y) the fair market value. The “fair market value” shall mean the average reported last sale price of the Company’s common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. Whether the Company will exercise our option to require all holders to exercise their warrants on a “cashless basis” will depend on a variety of factors including the price of our common shares at the time the warrants are called for redemption, its cash needs at such time and concerns regarding dilutive share issuances. 

 

If (x) the Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of its initial business combination at an issue price or effective issue price of less than $9.50 per share of common stock (with such issue price or effective issue price to be determined in good faith by its board of directors, and in the case of any such issuance to its sponsor, initial stockholders or their affiliates, without taking into account any founders’ shares held by them prior to such issuance), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of our initial business combination on the date of the consummation of our initial business combination (net of redemptions), and (z) the Market Value is below $9.50 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of (i) the Market Value or (ii) the price at which the Company issues the additional shares of common stock or equity-linked securities and the $16.50 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to 165% of the Market Value. The warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price, by certified or official bank check payable to the Company, for the number of warrants being exercised. The warrant holders do not have the rights or privileges of holders of shares of common stock and any voting rights until they exercise their warrants and receive shares of common stock. After the issuance of shares of common stock upon exercise of the warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by stockholders.

 

Private Warrants

 

The private warrants are identical to the warrants sold as part of the public units in this offering except that the private warrants will be non-redeemable and may be exercised on a cashless basis, in each case so long as they continue to be held by the initial purchasers or their permitted transferees. Additionally, if public units or shares of common stock are purchased by any of the directors, officers or initial stockholders, they will be entitled to funds from the trust account to the same extent as any public stockholder upon our liquidation but will not have redemption rights related thereto.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements
 6 Months Ended
Jun. 30, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurements

Note 9 — Fair Value Measurements

 

The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis at June 30, 2021, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:

 

   June 30,             
   2021   (Level 1)   (Level 2)   (Level 3) 
Assets:                
Mutual Funds held in Trust Account  $203,272,741   $203,272,741   $
—
   $
—
 
   $203,272,741   $203,272,741   $
—
   $
—
 
Liabilities:                    
Private Warrant Liability  $6,631,815   $
—
   $
—
    6,631,815 
   $6,631,815   $
—
   $
—
   $6,631,815 

 

The Warrants are accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liabilities on the Condensed Balance Sheet. The warrant liabilities were measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrant liabilities in the Condensed Statement of Operations.

 

The Company established the initial fair value of the Private Warrants on December 28, 2020, the date of the Company’s Initial Public Offering, and revalued on December 31, 2020 and on June 30, 2021 , using a Monte Carlo simulation model. The Warrants were classified as Level 3 at the initial measurement date due to the use of unobservable inputs.

  

The key inputs into the Monte Carlo simulation as of December 31, 2020 and June 30, 2021 were as follows:

 

Inputs  December 31,
2020		   June 30,
2021		 
Risk-free interest rate   0.52%   0.98%
Expected term remaining (years)   6.12    5.63 
Expected volatility   24.2%   13.4%
Stock price  $9.625   $9.900 

 

The change in the fair value of the Private Warrant liability for the period ended June 30, 2021 is summarized as follows:

 

Fair value at December 31, 2020  $10,763,361 
Change in fair value   (4,131,546)
Fair Value at June 30, 2021  $6,631,815 
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Subsequent Events
 6 Months Ended
Jun. 30, 2021
Subsequent Events [Abstract]  
Subsequent Events

Note 10 — Subsequent Events

 

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Accounting Policies, by Policy (Policies)
 6 Months Ended
Jun. 30, 2021
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation 

 

The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented.

  

The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K/A for the year ended December 31, 2020 as filed with the SEC on July 2, 2021, which contains the audited financial statements and notes thereto. The interim results for the six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any future interim periods.

 
Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

 
Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The cash equivalents in the amount of $950,419 and $3,092,771, were held in money market funds as of June 30, 2021 and December 31, 2020, respectively.

 
Marketable securities held in Trust Account

Marketable Securities Held in Trust Account

 

At June 30, 2021 and December 31, 2020, substantially all of the assets held in the Trust Account were held in mutual funds which invest in U.S. Treasury securities. The mutual fund assets in the amount of $203,272,741 and $203,262,660 were held in the Trust Account as of June 30, 2021 and December 31, 2020, respectively.

 
Warrant Liabilities

Warrants

 

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date for Private Warrants while the warrants are outstanding.

 

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance and recorded as a warrant liability. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations.

 
Common Stock Subject to Possible Redemption

Common Stock Subject to Possible Redemption

 

The Company accounts for its common stock subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Common stock subject to mandatory redemption (if any) is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock feature certain redemption right that is considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet. At June 30, 2021 and December 31, 2020, 18,396,227 and 18,084,699 shares of common stock subject to possible redemption are presented as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet.

 
Income Taxes

Income Taxes 

 

The Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, “Income Taxes” (“ASC 740”). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

 

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of June 30, 2021. The Company’s management determined that the United States is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties for the three-month period ending June 30, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.

 
Net Income Per Common Share

Net Income Per Common Share

 

Net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. The calculation of diluted loss per common share does not consider the effect of the warrants issued in connection with the (i) IPO, (ii) exercise of over-allotment and (iii) Private Placement since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. The warrants are exercisable to purchase 19,062,500 shares of common stock in the aggregate.

 

The Company’s statement of operations includes a presentation of net income per share for common stock subject to possible redemption in a manner similar to the two-class method. Net income per common share, basic and diluted, for redeemable Common Stock is calculated by dividing the interest income earned on the Trust Account, net of applicable franchise and income taxes, by the weighted average number of redeemable common stock outstanding since original issuance.

 
Reconciliation of Net Income per Common Share

Reconciliation of Net Income per Common Share

 

Net income per common share, basic and diluted, for redeemable common stock is calculated by dividing the interest income earned on the Trust Account, by the weighted average number of redeemable common stock outstanding since original issuance. Net income per common stock, basic and diluted, for non-redeemable Common Stock is calculated by dividing the net income, adjusted for income attributable to redeemable common stock, by the weighted average number of non-redeemable common stock outstanding for the periods. Non-redeemable common stock includes the Founder Shares as these shares of common stock do not have any redemption features and do not participate in the income earned on the Trust Account. Accordingly, basic and diluted income per common share is calculated as follows:

 

   Three Months
Ended
June 30,
2021		   Six Months
Ended
June 30,
2021		 
Common stock subject to possible redemption        
Numerator: Net income allocable to common stock subject to possible redemption        
Accretion of interest income on marketable securities held in trust  $5,069   $10,081 
Less: interest available to be withdrawn for payment of taxes   (5,069)   (10,081)
Net income allocable to Common Stock subject to possible redemption  $
—
   $— 
Denominator: Weighted Average Redeemable Common Stock          
Redeemable Common Stock, Basic and Diluted   18,436,292    18,263,412 
Basic and Diluted net income per share, Redeemable Common Stock  $0.00   $0.00 
           
Non-Redeemable Common Stock          
Numerator: Net (Loss) Income minus Redeemable Net Earnings          
Net income  $(409,152)  $3,172,181 
Redeemable Net Earnings   
—
    — 
Non-Redeemable Net income  $(409,152)  $3,172,181 
Denominator: Weighted Average Non-Redeemable Common Stock          
Basic and diluted weighted average shares outstanding, Common Stock   6,719,958    6,892,838 
Basic and diluted net income per share, Common Stock  $(0.06)  $0.46 

 
Concentration of Credit Risk

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

 
Fair Value Measurements

Fair Value Measurements

 

Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:

 

  ● Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;

 

  ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

 

  ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 
Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

The fair value of the Company’s assets and liabilities, (excluding the warrant liability) which qualify as financial instruments under the Financial Accounting Standards Board (“FASB”) ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the balance sheet primarily due to their short-term nature.

 
Derivative Financial Instruments

Derivative Financial Instruments

 

The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. The Company’s derivative instruments are recorded at fair value and re-valued at each reporting date, with changes in the fair value reported in the statements of operations. Derivative assets and liabilities are classified on the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. The Company has determined the warrants are a derivative instrument. As the warrants meet the definition of a derivative the warrants are measured at fair value at issuance and at each reporting date in accordance with ASC 820, Fair Value Measurement, with changes in fair value recognized in the statement of operations in the period of change. In accordance with ASC 825-10 “Financial Instruments”, the Company has concluded that a portion of the transaction costs which directly related to the IPO and the Private Placement, should be allocated to the Warrants based on their relative fair value against total proceeds, and recognized as transaction costs in the statement of operations.

 
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Significant Accounting Policies (Tables)
 6 Months Ended
Jun. 30, 2021
Accounting Policies [Abstract]  
Schedule of net loss per common share, basic and diluted, for redeemable and non-redeemable common stock
   Three Months
Ended
June 30,
2021		   Six Months
Ended
June 30,
2021		 
Common stock subject to possible redemption        
Numerator: Net income allocable to common stock subject to possible redemption        
Accretion of interest income on marketable securities held in trust  $5,069   $10,081 
Less: interest available to be withdrawn for payment of taxes   (5,069)   (10,081)
Net income allocable to Common Stock subject to possible redemption  $
—
   $— 
Denominator: Weighted Average Redeemable Common Stock          
Redeemable Common Stock, Basic and Diluted   18,436,292    18,263,412 
Basic and Diluted net income per share, Redeemable Common Stock  $0.00   $0.00 
           
Non-Redeemable Common Stock          
Numerator: Net (Loss) Income minus Redeemable Net Earnings          
Net income  $(409,152)  $3,172,181 
Redeemable Net Earnings   
—
    — 
Non-Redeemable Net income  $(409,152)  $3,172,181 
Denominator: Weighted Average Non-Redeemable Common Stock          
Basic and diluted weighted average shares outstanding, Common Stock   6,719,958    6,892,838 
Basic and diluted net income per share, Common Stock  $(0.06)  $0.46 

 
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements (Tables)
 6 Months Ended
Jun. 30, 2021
Fair Value Disclosures [Abstract]  
Schedule of assets and liabilities that are measured at fair value on a recurring basis
   June 30,             
   2021   (Level 1)   (Level 2)   (Level 3) 
Assets:                
Mutual Funds held in Trust Account  $203,272,741   $203,272,741   $
—
   $
—
 
   $203,272,741   $203,272,741   $
—
   $
—
 
Liabilities:                    
Private Warrant Liability  $6,631,815   $
—
   $
—
    6,631,815 
   $6,631,815   $
—
   $
—
   $6,631,815 

 
Schedule of key inputs into the Monte Carlo simulation
Inputs  December 31,
2020		   June 30,
2021		 
Risk-free interest rate   0.52%   0.98%
Expected term remaining (years)   6.12    5.63 
Expected volatility   24.2%   13.4%
Stock price  $9.625   $9.900 

 
Schedule of change in fair value of private placement warrant liabilities
Fair value at December 31, 2020  $10,763,361 
Change in fair value   (4,131,546)
Fair Value at June 30, 2021  $6,631,815 
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Organization and Business Operation (Details)
 6 Months Ended
Jun. 30, 2021
USD ($)
$ / shares
shares
Organization and Business Operation (Details) [Line Items]  
Maturity term 180 days
Initial business combination percentage of trust account 80.00%
Percentage of outstanding voting securities 50.00%
Business combination net tangible assets (in Dollars) $ 5,000,001
Aggregate percent of shares sold 20.00%
Redemption of public shares percentage 100.00%
Outstanding public shares percentage 100.00%
Cash held outside the Trust Account (in Dollars) $ 1,056,622
Value of trust account (in Dollars) $ 1,056,622
IPO [Member]  
Organization and Business Operation (Details) [Line Items]  
Sale of over allotment units (in Shares) | shares 203,262,500
Share price (in Dollars per share) | $ / shares $ 10.10
Redemption percentage of outstanding public shares 100.00%
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Significant Accounting Policies (Details) - USD ($)
 5 Months Ended 6 Months Ended
Dec. 31, 2020
Jun. 30, 2021
Accounting Policies [Abstract]    
Cash equivalents $ 3,092,771 $ 950,419
Mutual fund assets held in trust account $ 203,262,660 $ 203,272,741
Shares of common stock subject to possible redemption (in Shares) 18,084,699 18,396,227
Warrants exercisable to purchase shares of common stock (in Shares)   19,062,500
Federal depository insurance coverage amount   $ 250,000
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Significant Accounting Policies (Details) - Schedule of net loss per common share, basic and diluted, for redeemable and non-redeemable common stock - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2021
Numerator: Net income allocable to common stock subject to possible redemption    
Accretion of interest income on marketable securities held in trust $ 5,069 $ 10,081
Less: interest available to be withdrawn for payment of taxes (5,069) $ (10,081)
Net income allocable to Common Stock subject to possible redemption  
Denominator: Weighted Average Redeemable Common Stock    
Redeemable Common Stock, Basic and Diluted (in Shares) 18,436,292 18,263,412
Basic and Diluted net income per share, Redeemable Common Stock (in Shares) 0.00 0.00
Numerator: Net (Loss) Income minus Redeemable Net Earnings    
Net income $ (409,152) $ 3,172,181
Redeemable Net Earnings  
Non-Redeemable Net income $ (409,152) $ 3,172,181
Denominator: Weighted Average Non-Redeemable Common Stock    
Basic and diluted weighted average shares outstanding, Common Stock (in Shares) 6,719,958 6,892,838
Basic and diluted net income per share, Common Stock (in Dollars per share) $ (0.06) $ 0.46
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Initial Public Offering (Details)
 1 Months Ended
Dec. 28, 2020
USD ($)
$ / shares
shares
IPO [Member]  
Initial Public Offering (Details) [Line Items]  
Sale of stock 17,500,000
Share Price (in Dollars per share) | $ / shares $ 10.00
Sale of stock Description Each Unit consists of one share of Common Stock, par value $0.0001 per share, one redeemable warrant (the “Public Warrants”) and one right. Each right entitles the holder thereof to receive one-twentieth (1/20) of a share of common stock upon consummation of our initial business combination.
Over-Allotment Option [Member]  
Initial Public Offering (Details) [Line Items]  
Sale of stock 2,625,000
Gross proceeds (in Dollars) | $ $ 26,250,000
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Private Placement (Details) - Private Placement [Member]
 6 Months Ended
Jun. 30, 2021
USD ($)
$ / shares
shares
Private Placement (Details) [Line Items]  
Number of warrants purchased (in Shares) | shares 18,000,000
Price per warrant $ 0.50
Proceeds from issuance of warrants (in Dollars) | $ $ 9,000,000
Price per share $ 11.50
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Related Party Transactions (Details) - USD ($)
 1 Months Ended 6 Months Ended
Dec. 03, 2020
Dec. 30, 2020
Dec. 22, 2020
Aug. 31, 2020
Jun. 30, 2021
Dec. 31, 2020
Related Party Transactions (Details) [Line Items]            
Common stock par value (in Dollars per share)         $ 0.0001 $ 0.0001
Shares outstanding 4,887,500          
Shares cancellation common stock subject to forfeiture         656,250  
Incurred of administrative service fees (in Dollars)         $ 120,000  
Accruedof administrative service fees (in Dollars)         $ 110,000  
Founder Shares [Member]            
Related Party Transactions (Details) [Line Items]            
Payment to sponsor (in Dollars)       $ 25,000    
Price per share paid (in Dollars per share)       $ 0.007    
Consideration shares       3,593,750    
Common stock par value (in Dollars per share)       $ 0.0001    
Share dividend 0.36   0.03      
Aggregate shares     5,031,250      
Shares subject to forfeiture     656,250      
Aggregate share of common stock     1,006,250      
Founder shares related, description         50% of these shares will not be transferred, assigned, sold or released from escrow until the earlier of (i) 6 months after the date of the consummation of the Company’s initial business combination or (ii) the date on which the closing price of the Company’s shares of common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing after its initial business combination and the remaining 50% of the founder shares will not be transferred, assigned, sold or released from escrow until 6 months after the date of the consummation of the Company’s initial business combination, or earlier, in either case, if, subsequent to its initial business combination, the Company consummates a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of its stockholders having the right to exchange their shares of common stock for cash, securities or other property.  
Over-Allotment Option [Member]            
Related Party Transactions (Details) [Line Items]            
Aggregate share of common stock     875,000      
Shares cancellation common stock subject to forfeiture   656,250        
Sponsor [Member]            
Related Party Transactions (Details) [Line Items]            
Expenses related to IPO (in Dollars)         $ 500,000  
IPO [Member]            
Related Party Transactions (Details) [Line Items]            
Promissory note amount (in Dollars)         228,758  
Sponsor [Member]            
Related Party Transactions (Details) [Line Items]            
Payment for office space (in Dollars)         $ 20,000  
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies (Details)
 6 Months Ended
Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
Underwriting fee description The underwriters were entitled to deferred underwriting fee of 3.5% of the gross proceeds of the IPO, or $7,043,750 in the aggregate.
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholders’ Equity (Details) - $ / shares
 5 Months Ended 6 Months Ended
Dec. 31, 2020
Jun. 30, 2021
Stockholders' Equity Note [Abstract]    
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized 60,000,000 60,000,000
Common stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Description of common stock   Holders are entitled to one vote for each share of common stock.
Common Stock, Shares Issued 7,071,551 6,760,023
Common stock, shares outstanding 7,071,551 6,760,023
Common stock subject to possible redemption 18,084,699 18,396,227
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Warrants (Details)
 6 Months Ended
Jun. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Description of public warrants Each warrant entitles the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $11.50 per whole share, subject to adjustment as described in this prospectus. Each right entitles the holder thereof to receive one-twentieth (1/20) of a share of common stock upon consummation of our initial business combination. Pursuant to the warrant agreement, a warrant holder may exercise its public warrants only for a whole number of shares. This means that only an even number of public warrants may be exercised at any given time by a warrant holder.
Warrants redemption, description ●in whole and not in part;    ●at a price of $0.01 per warrant;    ●upon not less than 30 days’ prior written notice of redemption (the “30-day redemption period”) to each warrant holder; and    ●if and only if, there is a current registration statement in effect with respect to the shares of common stock underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption.
Equity linked securities, Description If (x) the Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of its initial business combination at an issue price or effective issue price of less than $9.50 per share of common stock (with such issue price or effective issue price to be determined in good faith by its board of directors, and in the case of any such issuance to its sponsor, initial stockholders or their affiliates, without taking into account any founders’ shares held by them prior to such issuance), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of our initial business combination on the date of the consummation of our initial business combination (net of redemptions), and (z) the Market Value is below $9.50 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of (i) the Market Value or (ii) the price at which the Company issues the additional shares of common stock or equity-linked securities and the $16.50 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to 165% of the Market Value. The warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price, by certified or official bank check payable to the Company, for the number of warrants being exercised. The warrant holders do not have the rights or privileges of holders of shares of common stock and any voting rights until they exercise their warrants and receive shares of common stock. After the issuance of shares of common stock upon exercise of the warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by stockholders. 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value on a recurring basis
 6 Months Ended
Jun. 30, 2021
USD ($)
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value on a recurring basis [Line Items]  
Total assets $ 203,272,741
Total liabilities 6,631,815
Mutual Funds held in Trust Account [Member]  
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value on a recurring basis [Line Items]  
Total assets 203,272,741
Private Placement Warrants Liability [Member]  
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value on a recurring basis [Line Items]  
Total liabilities 6,631,815
Level 1 [Member]  
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value on a recurring basis [Line Items]  
Total assets 203,272,741
Total liabilities
Level 1 [Member] | Mutual Funds held in Trust Account [Member]  
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value on a recurring basis [Line Items]  
Total assets 203,272,741
Level 1 [Member] | Private Placement Warrants Liability [Member]  
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value on a recurring basis [Line Items]  
Total liabilities
Level 2 [Member]  
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value on a recurring basis [Line Items]  
Total assets
Total liabilities
Level 2 [Member] | Mutual Funds held in Trust Account [Member]  
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value on a recurring basis [Line Items]  
Total assets
Level 2 [Member] | Private Placement Warrants Liability [Member]  
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value on a recurring basis [Line Items]  
Total liabilities
Level 3 [Member]  
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value on a recurring basis [Line Items]  
Total assets
Total liabilities 6,631,815
Level 3 [Member] | Mutual Funds held in Trust Account [Member]  
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value on a recurring basis [Line Items]  
Total assets
Level 3 [Member] | Private Placement Warrants Liability [Member]  
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value on a recurring basis [Line Items]  
Total liabilities $ 6,631,815
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements (Details) - Schedule of key inputs into the Monte Carlo simulation - $ / shares
 5 Months Ended 6 Months Ended
Dec. 31, 2020
Jun. 30, 2021
Schedule of key inputs into the Monte Carlo simulation [Abstract]    
Risk-free interest rate 0.52% 0.98%
Expected term remaining (years) 6 years 1 month 13 days 5 years 7 months 17 days
Expected volatility 24.20% 13.40%
Stock price (in Dollars per share) $ 9.625 $ 9.900
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements (Details) - Schedule of change in fair value of private placement warrant liabilities
 6 Months Ended
Jun. 30, 2021
USD ($)
Schedule of change in fair value of private placement warrant liabilities [Abstract]  
Fair value at December 31, 2020 $ 10,763,361
Change in fair value (4,131,546)
Fair Value at June 30, 2021 $ 6,631,815
EXCEL 42 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 43 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 44 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 45 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 53 241 1 false 14 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.viveohealth.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Balance Sheets Sheet http://www.viveohealth.com/role/ConsolidatedBalanceSheet Condensed Balance Sheets Statements 2 false false R3.htm 002 - Statement - Condensed Balance Sheets (Parentheticals) Sheet http://www.viveohealth.com/role/ConsolidatedBalanceSheet_Parentheticals Condensed Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://www.viveohealth.com/role/ConsolidatedIncomeStatement Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Statement of Changes in Stockholders??? Equity (Unaudited) Sheet http://www.viveohealth.com/role/ShareholdersEquityType2or3 Condensed Statement of Changes in Stockholders??? Equity (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Statement of Cash Flows (Unaudited) Sheet http://www.viveohealth.com/role/ConsolidatedCashFlow Condensed Statement of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Organization and Business Operation Sheet http://www.viveohealth.com/role/OrganizationandBusinessOperation Organization and Business Operation Notes 7 false false R8.htm 007 - Disclosure - Significant Accounting Policies Sheet http://www.viveohealth.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 8 false false R9.htm 008 - Disclosure - Initial Public Offering Sheet http://www.viveohealth.com/role/InitialPublicOffering Initial Public Offering Notes 9 false false R10.htm 009 - Disclosure - Private Placement Sheet http://www.viveohealth.com/role/PrivatePlacement Private Placement Notes 10 false false R11.htm 010 - Disclosure - Related Party Transactions Sheet http://www.viveohealth.com/role/RelatedPartyTransactions Related Party Transactions Notes 11 false false R12.htm 011 - Disclosure - Commitments and Contingencies Sheet http://www.viveohealth.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 12 false false R13.htm 012 - Disclosure - Stockholders??? Equity Sheet http://www.viveohealth.com/role/StockholdersEquity Stockholders??? Equity Notes 13 false false R14.htm 013 - Disclosure - Warrants Sheet http://www.viveohealth.com/role/Warrants Warrants Notes 14 false false R15.htm 014 - Disclosure - Fair Value Measurements Sheet http://www.viveohealth.com/role/FairValueMeasurements Fair Value Measurements Notes 15 false false R16.htm 015 - Disclosure - Subsequent Events Sheet http://www.viveohealth.com/role/SubsequentEvents Subsequent Events Notes 16 false false R17.htm 016 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://www.viveohealth.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://www.viveohealth.com/role/SignificantAccountingPolicies 17 false false R18.htm 017 - Disclosure - Significant Accounting Policies (Tables) Sheet http://www.viveohealth.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://www.viveohealth.com/role/SignificantAccountingPolicies 18 false false R19.htm 018 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.viveohealth.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.viveohealth.com/role/FairValueMeasurements 19 false false R20.htm 019 - Disclosure - Organization and Business Operation (Details) Sheet http://www.viveohealth.com/role/OrganizationandBusinessOperationDetails Organization and Business Operation (Details) Details http://www.viveohealth.com/role/OrganizationandBusinessOperation 20 false false R21.htm 020 - Disclosure - Significant Accounting Policies (Details) Sheet http://www.viveohealth.com/role/SignificantAccountingPoliciesDetails Significant Accounting Policies (Details) Details http://www.viveohealth.com/role/SignificantAccountingPoliciesTables 21 false false R22.htm 021 - Disclosure - Significant Accounting Policies (Details) - Schedule of net loss per common share, basic and diluted, for redeemable and non-redeemable common stock Sheet http://www.viveohealth.com/role/ScheduleofnetlosspercommonsharebasicanddilutedforredeemableandnonredeemablecommonstockTable Significant Accounting Policies (Details) - Schedule of net loss per common share, basic and diluted, for redeemable and non-redeemable common stock Details http://www.viveohealth.com/role/SignificantAccountingPoliciesTables 22 false false R23.htm 022 - Disclosure - Initial Public Offering (Details) Sheet http://www.viveohealth.com/role/InitialPublicOfferingDetails Initial Public Offering (Details) Details http://www.viveohealth.com/role/InitialPublicOffering 23 false false R24.htm 023 - Disclosure - Private Placement (Details) Sheet http://www.viveohealth.com/role/PrivatePlacementDetails Private Placement (Details) Details http://www.viveohealth.com/role/PrivatePlacement 24 false false R25.htm 024 - Disclosure - Related Party Transactions (Details) Sheet http://www.viveohealth.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.viveohealth.com/role/RelatedPartyTransactions 25 false false R26.htm 025 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.viveohealth.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.viveohealth.com/role/CommitmentsandContingencies 26 false false R27.htm 026 - Disclosure - Stockholders??? Equity (Details) Sheet http://www.viveohealth.com/role/StockholdersEquityDetails Stockholders??? Equity (Details) Details http://www.viveohealth.com/role/StockholdersEquity 27 false false R28.htm 027 - Disclosure - Warrants (Details) Sheet http://www.viveohealth.com/role/WarrantsDetails Warrants (Details) Details http://www.viveohealth.com/role/Warrants 28 false false R29.htm 028 - Disclosure - Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value on a recurring basis Sheet http://www.viveohealth.com/role/ScheduleofassetsandliabilitiesthataremeasuredatfairvalueonarecurringbasisTable Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value on a recurring basis Details http://www.viveohealth.com/role/FairValueMeasurementsTables 29 false false R30.htm 029 - Disclosure - Fair Value Measurements (Details) - Schedule of key inputs into the Monte Carlo simulation Sheet http://www.viveohealth.com/role/ScheduleofkeyinputsintotheMonteCarlosimulationTable Fair Value Measurements (Details) - Schedule of key inputs into the Monte Carlo simulation Details http://www.viveohealth.com/role/FairValueMeasurementsTables 30 false false R31.htm 030 - Disclosure - Fair Value Measurements (Details) - Schedule of change in fair value of private placement warrant liabilities Sheet http://www.viveohealth.com/role/ScheduleofchangeinfairvalueofprivateplacementwarrantliabilitiesTable Fair Value Measurements (Details) - Schedule of change in fair value of private placement warrant liabilities Details http://www.viveohealth.com/role/FairValueMeasurementsTables 31 false false All Reports Book All Reports f10q0621_viveonhealthacq.htm f10q0621ex31-1_viveonhealth.htm f10q0621ex31-2_viveonhealth.htm f10q0621ex32_viveonhealth.htm vhaq-20210630.xsd vhaq-20210630_cal.xml vhaq-20210630_def.xml vhaq-20210630_lab.xml vhaq-20210630_pre.xml http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021 true true JSON 47 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f10q0621_viveonhealthacq.htm": { "axisCustom": 0, "axisStandard": 5, "contextCount": 53, "dts": { "calculationLink": { "local": [ "vhaq-20210630_cal.xml" ] }, "definitionLink": { "local": [ "vhaq-20210630_def.xml" ] }, "inline": { "local": [ "f10q0621_viveonhealthacq.htm" ] }, "labelLink": { "local": [ "vhaq-20210630_lab.xml" ], "remote": [ "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-doc-2021-01-31.xml" ] }, "presentationLink": { "local": [ "vhaq-20210630_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-ref-2021-01-31.xml" ] }, "schema": { "local": [ "vhaq-20210630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-parts-codification-2021-01-31.xsd" ] } }, "elementCount": 248, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 28, "http://xbrl.sec.gov/dei/2021": 4, "total": 32 }, "keyCustom": 38, "keyStandard": 203, "memberCustom": 4, "memberStandard": 9, "nsprefix": "vhaq", "nsuri": "http://www.viveohealth.com/20210630", "report": { "R1": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.viveohealth.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "vhaq:PrivatePlacementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Private Placement", "role": "http://www.viveohealth.com/role/PrivatePlacement", "shortName": "Private Placement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "vhaq:PrivatePlacementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Related Party Transactions", "role": "http://www.viveohealth.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Commitments and Contingencies", "role": "http://www.viveohealth.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Stockholders\u2019 Equity", "role": "http://www.viveohealth.com/role/StockholdersEquity", "shortName": "Stockholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Warrants", "role": "http://www.viveohealth.com/role/Warrants", "shortName": "Warrants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Fair Value Measurements", "role": "http://www.viveohealth.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Subsequent Events", "role": "http://www.viveohealth.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Accounting Policies, by Policy (Policies)", "role": "http://www.viveohealth.com/role/AccountingPoliciesByPolicy", "shortName": "Accounting Policies, by Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Significant Accounting Policies (Tables)", "role": "http://www.viveohealth.com/role/SignificantAccountingPoliciesTables", "shortName": "Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.viveohealth.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Condensed Balance Sheets", "role": "http://www.viveohealth.com/role/ConsolidatedBalanceSheet", "shortName": "Condensed Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "vhaq:MaturityTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Organization and Business Operation (Details)", "role": "http://www.viveohealth.com/role/OrganizationandBusinessOperationDetails", "shortName": "Organization and Business Operation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "vhaq:MaturityTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Significant Accounting Policies (Details)", "role": "http://www.viveohealth.com/role/SignificantAccountingPoliciesDetails", "shortName": "Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccretionExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Significant Accounting Policies (Details) - Schedule of net loss per common share, basic and diluted, for redeemable and non-redeemable common stock", "role": "http://www.viveohealth.com/role/ScheduleofnetlosspercommonsharebasicanddilutedforredeemableandnonredeemablecommonstockTable", "shortName": "Significant Accounting Policies (Details) - Schedule of net loss per common share, basic and diluted, for redeemable and non-redeemable common stock", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccretionExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c24", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Initial Public Offering (Details)", "role": "http://www.viveohealth.com/role/InitialPublicOfferingDetails", "shortName": "Initial Public Offering (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c24", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c27", "decimals": "INF", "first": true, "lang": null, "name": "vhaq:NumberOfWarrantsPurchased", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Private Placement (Details)", "role": "http://www.viveohealth.com/role/PrivatePlacementDetails", "shortName": "Private Placement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c27", "decimals": "INF", "first": true, "lang": null, "name": "vhaq:NumberOfWarrantsPurchased", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c2", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Related Party Transactions (Details)", "role": "http://www.viveohealth.com/role/RelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c32", "decimals": "INF", "lang": null, "name": "vhaq:ShareOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "vhaq:UnderwritingFeeDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.viveohealth.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "vhaq:UnderwritingFeeDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesAuthorized", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Stockholders\u2019 Equity (Details)", "role": "http://www.viveohealth.com/role/StockholdersEquityDetails", "shortName": "Stockholders\u2019 Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "lang": "en-US", "name": "us-gaap:CommonStockVotingRights", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DescriptionOfPriceRiskDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsActivities", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Warrants (Details)", "role": "http://www.viveohealth.com/role/WarrantsDetails", "shortName": "Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DescriptionOfPriceRiskDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsActivities", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AssetsHeldInTrustCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value on a recurring basis", "role": "http://www.viveohealth.com/role/ScheduleofassetsandliabilitiesthataremeasuredatfairvalueonarecurringbasisTable", "shortName": "Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value on a recurring basis", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AssetsHeldInTrustCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c2", "decimals": "INF", "first": true, "lang": null, "name": "vhaq:CommonStockSubjectToPossibleRedemptionShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Condensed Balance Sheets (Parentheticals)", "role": "http://www.viveohealth.com/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Condensed Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c2", "decimals": "INF", "first": true, "lang": null, "name": "vhaq:CommonStockSubjectToPossibleRedemptionShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c23", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Fair Value Measurements (Details) - Schedule of key inputs into the Monte Carlo simulation", "role": "http://www.viveohealth.com/role/ScheduleofkeyinputsintotheMonteCarlosimulationTable", "shortName": "Fair Value Measurements (Details) - Schedule of key inputs into the Monte Carlo simulation", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c23", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueNetAssetLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Fair Value Measurements (Details) - Schedule of change in fair value of private placement warrant liabilities", "role": "http://www.viveohealth.com/role/ScheduleofchangeinfairvalueofprivateplacementwarrantliabilitiesTable", "shortName": "Fair Value Measurements (Details) - Schedule of change in fair value of private placement warrant liabilities", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueNetAssetLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingCostsAndExpenses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Condensed Statements of Operations (Unaudited)", "role": "http://www.viveohealth.com/role/ConsolidatedIncomeStatement", "shortName": "Condensed Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingCostsAndExpenses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c5", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Condensed Statement of Changes in Stockholders\u2019 Equity (Unaudited)", "role": "http://www.viveohealth.com/role/ShareholdersEquityType2or3", "shortName": "Condensed Statement of Changes in Stockholders\u2019 Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c5", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Condensed Statement of Cash Flows (Unaudited)", "role": "http://www.viveohealth.com/role/ConsolidatedCashFlow", "shortName": "Condensed Statement of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "vhaq:InterestEarnedOnCashHeldInTrustAccount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "006 - Disclosure - Organization and Business Operation", "role": "http://www.viveohealth.com/role/OrganizationandBusinessOperation", "shortName": "Organization and Business Operation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Significant Accounting Policies", "role": "http://www.viveohealth.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "vhaq:InitialPublicOfferingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Initial Public Offering", "role": "http://www.viveohealth.com/role/InitialPublicOffering", "shortName": "Initial Public Offering", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0621_viveonhealthacq.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "vhaq:InitialPublicOfferingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 14, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viveohealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r53", "r207", "r235", "r245" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties.", "label": "Accounts Payable, Related Parties", "terseLabel": "Other payable \u2013 related party" } } }, "localname": "AccountsPayableRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionExpense": { "auth_ref": [ "r100", "r101", "r102" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.", "label": "Accretion Expense", "terseLabel": "Accretion of interest income on marketable securities held in trust" } } }, "localname": "AccretionExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ScheduleofnetlosspercommonsharebasicanddilutedforredeemableandnonredeemablecommonstockTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r235", "r244" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.", "label": "Accrued Liabilities", "terseLabel": "Accrued costs and expenses" } } }, "localname": "AccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r11", "r159", "r214" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r56", "r57", "r58", "r156", "r157", "r158", "r185" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_Assets": { "auth_ref": [ "r52", "r87", "r89", "r93", "r96", "r108", "r109", "r110", "r112", "r113", "r114", "r115", "r116", "r117", "r119", "r120", "r170", "r176", "r196", "r212", "r214", "r233", "r240" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r7", "r25", "r52", "r96", "r108", "r109", "r110", "r112", "r113", "r114", "r115", "r116", "r117", "r119", "r120", "r170", "r176", "r196", "r212", "r214" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsHeldInTrust": { "auth_ref": [ "r50" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations.", "label": "Assets Held-in-trust", "terseLabel": "Mutual fund assets held in trust account" } } }, "localname": "AssetsHeldInTrust", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsHeldInTrustCurrent": { "auth_ref": [ "r50" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate within one year of the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.", "label": "Assets Held-in-trust, Current", "terseLabel": "Total assets" } } }, "localname": "AssetsHeldInTrustCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ScheduleofassetsandliabilitiesthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsHeldInTrustNoncurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.", "label": "Assets Held-in-trust, Noncurrent", "terseLabel": "Investment held in Trust Account" } } }, "localname": "AssetsHeldInTrustNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r2", "r55", "r85" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "Organization and Business Operation" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/OrganizationandBusinessOperation" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r16", "r214", "r252", "r253" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash and cash equivalents" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r16", "r47" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and cash equivalents, end of the period", "periodStartLabel": "Cash and cash equivalents, beginning of period" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ScheduleofassetsandliabilitiesthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r8", "r48" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r42", "r197" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net change in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r16" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash, FDIC Insured Amount", "terseLabel": "Federal depository insurance coverage amount" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Price per warrant" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/PrivatePlacementDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r23", "r106", "r236", "r243" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r103", "r104", "r105", "r107", "r254" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsShares": { "auth_ref": [ "r139" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits.", "label": "Common Stock Dividends, Shares", "terseLabel": "Share dividend" } } }, "localname": "CommonStockDividendsShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r56", "r57", "r185" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in Dollars per share)", "verboseLabel": "Common stock par value (in Dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.viveohealth.com/role/RelatedPartyTransactionsDetails", "http://www.viveohealth.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.viveohealth.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "verboseLabel": "Common Stock, Shares Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.viveohealth.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r10", "r139" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.viveohealth.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r10", "r214" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.0001 par value; 60,000,000 shares authorized; 6,760,023 and 7,071,551 shares issued and outstanding (excluding 18,396,227 and 18,084,699 shares subject to possible redemption) at June 30, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockVotingRights": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Common Stock, Voting Rights", "terseLabel": "Description of common stock" } } }, "localname": "CommonStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r79", "r239" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostsAndExpensesRelatedParty": { "auth_ref": [ "r37" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties.", "label": "Costs and Expenses, Related Party", "terseLabel": "Expenses related to IPO (in Dollars)" } } }, "localname": "CostsAndExpensesRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "auth_ref": [ "r21" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments applied to principal.", "label": "Debt Instrument, Periodic Payment, Principal", "terseLabel": "Promissory note amount (in Dollars)" } } }, "localname": "DebtInstrumentPeriodicPaymentPrincipal", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": { "auth_ref": [], "calculation": { "http://www.viveohealth.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).", "label": "Deferred Compensation Liability, Classified, Noncurrent", "terseLabel": "Deferred underwriting fee" } } }, "localname": "DeferredCompensationLiabilityClassifiedNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r184", "r187" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Warrants" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/Warrants" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r26", "r27", "r28", "r195" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Warrant liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r54", "r178", "r179", "r180", "r181", "r183" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Warrant Liabilities" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_DescriptionOfPriceRiskDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsActivities": { "auth_ref": [ "r178", "r180", "r181", "r182" ], "lang": { "en-us": { "role": { "documentation": "General discussion of the entity's activities involving price risk derivatives not designated as hedging instruments.", "label": "Description of Price Risk Derivative Instruments Not Designated as Hedging Instruments Activities", "terseLabel": "Description of public warrants" } } }, "localname": "DescriptionOfPriceRiskDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/WarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DueToOtherRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r18", "r53", "r207" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount payable to related parties classified as other, due within one year or the normal operating cycle, if longer.", "label": "Due to Other Related Parties, Current", "terseLabel": "Due to related party" } } }, "localname": "DueToOtherRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToOtherRelatedPartiesNoncurrent": { "auth_ref": [ "r22", "r53", "r207" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount payable from related parties classified as other, due after one year or the normal operating cycle, if longer.", "label": "Due to Other Related Parties, Noncurrent", "terseLabel": "Accruedof administrative service fees (in Dollars)" } } }, "localname": "DueToOtherRelatedPartiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r18", "r53", "r111", "r113", "r114", "r118", "r119", "r120", "r207" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Incurred of administrative service fees (in Dollars)" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Basic and diluted net income per share (in Dollars per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r74", "r75" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Income Per Common Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r32", "r33", "r34", "r56", "r57", "r58", "r60", "r65", "r67", "r76", "r97", "r139", "r141", "r156", "r157", "r158", "r167", "r168", "r185", "r198", "r199", "r200", "r201", "r202", "r203", "r247", "r248", "r249", "r262" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r45", "r124" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Change in fair value of warrant liability" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r190" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Schedule of key inputs into the Monte Carlo simulation" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r121", "r122", "r123", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r152", "r189", "r217", "r218", "r219" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ScheduleofassetsandliabilitiesthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r121", "r144", "r145", "r150", "r152", "r189", "r217" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ScheduleofassetsandliabilitiesthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r121", "r122", "r123", "r144", "r145", "r150", "r152", "r189", "r218" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ScheduleofassetsandliabilitiesthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r121", "r122", "r123", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r152", "r189", "r219" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ScheduleofassetsandliabilitiesthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease)", "terseLabel": "Change in fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ScheduleofchangeinfairvalueofprivateplacementwarrantliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r121", "r122", "r123", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r152", "r217", "r218", "r219" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ScheduleofassetsandliabilitiesthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetAssetLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of asset after deduction of liability.", "label": "Fair Value, Net Asset (Liability)", "periodEndLabel": "Fair Value at June 30, 2021", "periodStartLabel": "Fair value at December 31, 2020" } } }, "localname": "FairValueNetAssetLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ScheduleofchangeinfairvalueofprivateplacementwarrantliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r193", "r194" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "IPO [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/InitialPublicOfferingDetails", "http://www.viveohealth.com/role/OrganizationandBusinessOperationDetails", "http://www.viveohealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r31", "r161", "r162", "r163", "r164", "r165", "r166" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInDerivativeLiabilities": { "auth_ref": [ "r44" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).", "label": "Increase (Decrease) in Derivative Liabilities", "terseLabel": "Change in fair value of warrant liability" } } }, "localname": "IncreaseDecreaseInDerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "auth_ref": [ "r44" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.", "label": "Increase (Decrease) in Due to Related Parties", "terseLabel": "Due to related party" } } }, "localname": "IncreaseDecreaseInDueToRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": { "auth_ref": [ "r44" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.", "label": "Increase (Decrease) in Other Accrued Liabilities", "terseLabel": "Accrued costs and expenses" } } }, "localname": "IncreaseDecreaseInOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r44" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "calculation": { "http://www.viveohealth.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest Income, Other", "terseLabel": "Interest earned on bank account" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r38", "r86" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest earned on investments held in Trust Account" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r19", "r52", "r90", "r96", "r108", "r109", "r110", "r113", "r114", "r115", "r116", "r117", "r119", "r120", "r171", "r176", "r177", "r196", "r212", "r213" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r15", "r52", "r96", "r196", "r214", "r234", "r242" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r20", "r52", "r96", "r108", "r109", "r110", "r113", "r114", "r115", "r116", "r117", "r119", "r120", "r171", "r176", "r177", "r196", "r212", "r213", "r214" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueAdjustment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.", "label": "Liabilities, Fair Value Adjustment", "terseLabel": "Total liabilities" } } }, "localname": "LiabilitiesFairValueAdjustment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ScheduleofassetsandliabilitiesthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Marketable securities held in Trust Account" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r42" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows from Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r42", "r43", "r46" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r29", "r30", "r34", "r35", "r46", "r52", "r59", "r61", "r62", "r63", "r64", "r66", "r67", "r70", "r87", "r88", "r91", "r92", "r94", "r96", "r108", "r109", "r110", "r113", "r114", "r115", "r116", "r117", "r119", "r120", "r186", "r196", "r237", "r246" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.viveohealth.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income", "totalLabel": "Net (loss) income", "verboseLabel": "Net Income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedCashFlow", "http://www.viveohealth.com/role/ConsolidatedIncomeStatement", "http://www.viveohealth.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest": { "auth_ref": [ "r36" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Portion of net income (loss) attributable to nonredeemable noncontrolling interest.", "label": "Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest", "terseLabel": "Non-Redeemable Net income" } } }, "localname": "NetIncomeLossAttributableToNonredeemableNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ScheduleofnetlosspercommonsharebasicanddilutedforredeemableandnonredeemablecommonstockTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest": { "auth_ref": [ "r36" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.", "label": "Net Income (Loss) Attributable to Redeemable Noncontrolling Interest", "terseLabel": "Redeemable Net Earnings" } } }, "localname": "NetIncomeLossAttributableToRedeemableNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ScheduleofnetlosspercommonsharebasicanddilutedforredeemableandnonredeemablecommonstockTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r61", "r62", "r63", "r64", "r68", "r69", "r71", "r73", "r87", "r88", "r91", "r92", "r94" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net income allocable to Common Stock subject to possible redemption" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ScheduleofnetlosspercommonsharebasicanddilutedforredeemableandnonredeemablecommonstockTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": { "auth_ref": [ "r125", "r172", "r173" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.", "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest", "terseLabel": "Net income" } } }, "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ScheduleofnetlosspercommonsharebasicanddilutedforredeemableandnonredeemablecommonstockTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r39" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r17", "r53", "r208" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Notes Payable, Related Parties, Current", "terseLabel": "Promissory note \u2013 related party" } } }, "localname": "NotesPayableRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingCostsAndExpenses": { "auth_ref": [], "calculation": { "http://www.viveohealth.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.", "label": "Operating Costs and Expenses", "terseLabel": "Formation and operating costs" } } }, "localname": "OperatingCostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r87", "r88", "r91", "r92", "r94" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from Operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Component of Operating Income [Abstract]", "terseLabel": "Other income:" } } }, "localname": "OtherIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]", "terseLabel": "Over-Allotment Option [Member]" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/InitialPublicOfferingDetails", "http://www.viveohealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r9", "r126" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in Dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.viveohealth.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.viveohealth.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r9", "r126" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r9", "r214" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r4", "r6", "r98", "r99" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid Expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]", "terseLabel": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/PrivatePlacementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r40" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Gross proceeds (in Dollars)" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/InitialPublicOfferingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r40" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds from Issuance of Private Placement", "terseLabel": "Proceeds from issuance of warrants (in Dollars)" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/PrivatePlacementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": { "auth_ref": [], "calculation": { "http://www.viveohealth.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.", "label": "Proceeds from (Repayments of) Related Party Debt", "terseLabel": "Payment of other payable \u2013 related party" } } }, "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r151", "r206", "r207" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r151", "r206", "r209", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r204", "r205", "r207", "r210", "r211" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r41" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Repayments of Related Party Debt", "negatedLabel": "Payment of promissory note" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ScheduleofassetsandliabilitiesthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r12", "r141", "r159", "r214", "r241", "r250", "r251" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained Earnings (Accumulated deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r56", "r57", "r58", "r60", "r65", "r67", "r97", "r156", "r157", "r158", "r167", "r168", "r185", "r247", "r249" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings/ (Accumulated Deficit)" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockDescriptionOfTransaction": { "auth_ref": [ "r169", "r174", "r175" ], "lang": { "en-us": { "role": { "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.", "label": "Sale of Stock, Description of Transaction", "terseLabel": "Sale of stock Description" } } }, "localname": "SaleOfStockDescriptionOfTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/InitialPublicOfferingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/OrganizationandBusinessOperationDetails", "http://www.viveohealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Sale of over allotment units (in Shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/OrganizationandBusinessOperationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Share price (in Dollars per share)", "verboseLabel": "Price per share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/OrganizationandBusinessOperationDetails", "http://www.viveohealth.com/role/PrivatePlacementDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements.", "label": "Schedule of Changes in Fair Value of Plan Assets [Table Text Block]", "terseLabel": "Schedule of change in fair value of private placement warrant liabilities" } } }, "localname": "ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of net loss per common share, basic and diluted, for redeemable and non-redeemable common stock" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r188", "r189" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of assets and liabilities that are measured at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ScheduleofkeyinputsintotheMonteCarlosimulationTable" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r155" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ScheduleofkeyinputsintotheMonteCarlosimulationTable" ], "xbrltype": "percentItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Price per share paid (in Dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r153", "r160" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term remaining (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ScheduleofkeyinputsintotheMonteCarlosimulationTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognition of changes in redemption value of mandatorily redeemable shares. Provides the period over which changes in redemption value are accreted, usually from the issuance date (or from the date that it becomes probable that the security will become redeemable, if later) to the earliest redemption date of the security.", "label": "Shares Subject to Mandatory Redemption, Changes in Redemption Value, Policy [Policy Text Block]", "terseLabel": "Common Stock Subject to Possible Redemption" } } }, "localname": "SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r49", "r55" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r24", "r32", "r33", "r34", "r56", "r57", "r58", "r60", "r65", "r67", "r76", "r97", "r139", "r141", "r156", "r157", "r158", "r167", "r168", "r185", "r198", "r199", "r200", "r201", "r202", "r203", "r247", "r248", "r249", "r262" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r56", "r57", "r58", "r76", "r220" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Consideration shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r9", "r10", "r139", "r141" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Sale of stock" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/InitialPublicOfferingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Payment to sponsor (in Dollars)" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Value, Other", "terseLabel": "Deferred offering costs" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRedeemedOrCalledDuringPeriodShares": { "auth_ref": [ "r139" ], "lang": { "en-us": { "role": { "documentation": "Number of stock bought back by the entity at the exercise price or redemption price.", "label": "Stock Redeemed or Called During Period, Shares", "terseLabel": "Change in common stock subject to possible redemption (in Shares)" } } }, "localname": "StockRedeemedOrCalledDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRedeemedOrCalledDuringPeriodValue": { "auth_ref": [ "r139" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.", "label": "Stock Redeemed or Called During Period, Value", "terseLabel": "Change in common stock subject to possible redemption" } } }, "localname": "StockRedeemedOrCalledDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r10", "r13", "r14", "r52", "r95", "r96", "r196", "r214" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet", "http://www.viveohealth.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r51", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r141", "r142" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r215", "r216" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/InitialPublicOfferingDetails", "http://www.viveohealth.com/role/OrganizationandBusinessOperationDetails", "http://www.viveohealth.com/role/PrivatePlacementDetails", "http://www.viveohealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r108", "r113", "r114", "r115", "r119", "r120" ], "calculation": { "http://www.viveohealth.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "terseLabel": "Common Stock subject to possible redemption, 18,396,227 and 18,084,699 shares at redemption value at June 30, 2021 and December 31, 2020, respectively" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r77", "r78", "r80", "r81", "r82", "r83", "r84" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viveohealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "vhaq_AggregatePercentOfSharesSold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate percent of shares sold.", "label": "AggregatePercentOfSharesSold", "terseLabel": "Aggregate percent of shares sold" } } }, "localname": "AggregatePercentOfSharesSold", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/OrganizationandBusinessOperationDetails" ], "xbrltype": "percentItemType" }, "vhaq_AggregateShareOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate share of common stock.", "label": "AggregateShareOfCommonStock", "terseLabel": "Aggregate share of common stock" } } }, "localname": "AggregateShareOfCommonStock", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "vhaq_AggregateShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate shares.", "label": "AggregateShares", "terseLabel": "Aggregate shares" } } }, "localname": "AggregateShares", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "vhaq_AmountOfThresholdTangibleAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business combination net tangible assets.", "label": "AmountOfThresholdTangibleAssets", "terseLabel": "Business combination net tangible assets (in Dollars)" } } }, "localname": "AmountOfThresholdTangibleAssets", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/OrganizationandBusinessOperationDetails" ], "xbrltype": "monetaryItemType" }, "vhaq_BasicAndDilutedNetIncomePerShareRedeemableCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BasicAndDilutedNetIncomePerShareRedeemableCommonStock", "terseLabel": "Basic and Diluted net income per share, Redeemable Common Stock (in Shares)" } } }, "localname": "BasicAndDilutedNetIncomePerShareRedeemableCommonStock", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/ScheduleofnetlosspercommonsharebasicanddilutedforredeemableandnonredeemablecommonstockTable" ], "xbrltype": "sharesItemType" }, "vhaq_BasicAndDilutedNetLossPerShareNonredeemableCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Basic and diluted net loss per share non-redeemable common stock.", "label": "BasicAndDilutedNetLossPerShareNonredeemableCommonStock", "terseLabel": "Basic and diluted net (loss) income per share (in Dollars per share)", "verboseLabel": "Basic and diluted net income per share, Common Stock (in Dollars per share)" } } }, "localname": "BasicAndDilutedNetLossPerShareNonredeemableCommonStock", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedIncomeStatement", "http://www.viveohealth.com/role/ScheduleofnetlosspercommonsharebasicanddilutedforredeemableandnonredeemablecommonstockTable" ], "xbrltype": "perShareItemType" }, "vhaq_BasicAndDilutedWeightedAverageSharesOutstandingNonredeemableCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Basic and diluted, weighted average shares outstanding - non-redeemable common stock.", "label": "BasicAndDilutedWeightedAverageSharesOutstandingNonredeemableCommonStock", "terseLabel": "Basic and diluted, weighted average shares outstanding \u2013 non-redeemable common stock (in Shares)", "verboseLabel": "Basic and diluted weighted average shares outstanding, Common Stock (in Shares)" } } }, "localname": "BasicAndDilutedWeightedAverageSharesOutstandingNonredeemableCommonStock", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedIncomeStatement", "http://www.viveohealth.com/role/ScheduleofnetlosspercommonsharebasicanddilutedforredeemableandnonredeemablecommonstockTable" ], "xbrltype": "sharesItemType" }, "vhaq_BasicAndDilutedWeightedAverageSharesOutstandingRedeemableCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Basic and diluted, weighted average shares outstanding - redeemable common stock.", "label": "BasicAndDilutedWeightedAverageSharesOutstandingRedeemableCommonStock", "terseLabel": "Basic and diluted weighted average shares outstanding \u2013 redeemable common stock (in Shares)", "verboseLabel": "Redeemable Common Stock, Basic and Diluted (in Shares)" } } }, "localname": "BasicAndDilutedWeightedAverageSharesOutstandingRedeemableCommonStock", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedIncomeStatement", "http://www.viveohealth.com/role/ScheduleofnetlosspercommonsharebasicanddilutedforredeemableandnonredeemablecommonstockTable" ], "xbrltype": "sharesItemType" }, "vhaq_CashHeldOutsideTheTrustAccount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash held outside the Trust Account.", "label": "CashHeldOutsideTheTrustAccount", "terseLabel": "Cash held outside the Trust Account (in Dollars)" } } }, "localname": "CashHeldOutsideTheTrustAccount", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/OrganizationandBusinessOperationDetails" ], "xbrltype": "monetaryItemType" }, "vhaq_ChangesInOperatingAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ChangesInOperatingAssetsAndLiabilitiesAbstract", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "ChangesInOperatingAssetsAndLiabilitiesAbstract", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "vhaq_CommonStockSubjectToPossibleRedemption": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CommonStockSubjectToPossibleRedemption", "terseLabel": "Common stock subject to possible redemption" } } }, "localname": "CommonStockSubjectToPossibleRedemption", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "vhaq_CommonStockSubjectToPossibleRedemptionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CommonStockSubjectToPossibleRedemptionAbstract", "terseLabel": "Common stock subject to possible redemption" } } }, "localname": "CommonStockSubjectToPossibleRedemptionAbstract", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/ScheduleofnetlosspercommonsharebasicanddilutedforredeemableandnonredeemablecommonstockTable" ], "xbrltype": "stringItemType" }, "vhaq_CommonStockSubjectToPossibleRedemptionShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock subject to possible redemption shares.", "label": "CommonStockSubjectToPossibleRedemptionShares", "terseLabel": "Common stock subject to possible redemption shares" } } }, "localname": "CommonStockSubjectToPossibleRedemptionShares", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "vhaq_DenominatorWeightedAverageNonRedeemableCommonStockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DenominatorWeightedAverageNonRedeemableCommonStockAbstract", "terseLabel": "Denominator: Weighted Average Non-Redeemable Common Stock" } } }, "localname": "DenominatorWeightedAverageNonRedeemableCommonStockAbstract", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/ScheduleofnetlosspercommonsharebasicanddilutedforredeemableandnonredeemablecommonstockTable" ], "xbrltype": "stringItemType" }, "vhaq_DenominatorWeightedAverageRedeemableCommonStockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DenominatorWeightedAverageRedeemableCommonStockAbstract", "terseLabel": "Denominator: Weighted Average Redeemable Common Stock" } } }, "localname": "DenominatorWeightedAverageRedeemableCommonStockAbstract", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/ScheduleofnetlosspercommonsharebasicanddilutedforredeemableandnonredeemablecommonstockTable" ], "xbrltype": "stringItemType" }, "vhaq_DerivativeFinancialInstrumentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DerivativeFinancialInstrumentsPolicyTextBlock", "terseLabel": "Derivative Financial Instruments" } } }, "localname": "DerivativeFinancialInstrumentsPolicyTextBlock", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "vhaq_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.viveohealth.com/20210630", "xbrltype": "stringItemType" }, "vhaq_EquityLinkedSecuritiesDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EquityLinkedSecuritiesDescription", "terseLabel": "Equity linked securities, Description" } } }, "localname": "EquityLinkedSecuritiesDescription", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/WarrantsDetails" ], "xbrltype": "stringItemType" }, "vhaq_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesthataremeasuredatfairvalueonarecurringbasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value on a recurring basis [Line Items]" } } }, "localname": "FairValueMeasurementsDetailsScheduleofassetsandliabilitiesthataremeasuredatfairvalueonarecurringbasisLineItems", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/ScheduleofassetsandliabilitiesthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "stringItemType" }, "vhaq_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesthataremeasuredatfairvalueonarecurringbasisTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value on a recurring basis [Table]" } } }, "localname": "FairValueMeasurementsDetailsScheduleofassetsandliabilitiesthataremeasuredatfairvalueonarecurringbasisTable", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/ScheduleofassetsandliabilitiesthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "stringItemType" }, "vhaq_FounderSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FounderSharesMember", "terseLabel": "Founder Shares [Member]" } } }, "localname": "FounderSharesMember", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "vhaq_FounderSharesRelatedDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Founder shares related, description.", "label": "FounderSharesRelatedDescription", "terseLabel": "Founder shares related, description" } } }, "localname": "FounderSharesRelatedDescription", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "vhaq_InitialBusinessCombinationPercentageOfTrustAccount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial business combination percentage of trust account.", "label": "InitialBusinessCombinationPercentageOfTrustAccount", "terseLabel": "Initial business combination percentage of trust account" } } }, "localname": "InitialBusinessCombinationPercentageOfTrustAccount", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/OrganizationandBusinessOperationDetails" ], "xbrltype": "percentItemType" }, "vhaq_InitialClassificationOfCommonStockSubjectToPossibleRedemption": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Initial classification of common stock subject to possible redemption.", "label": "InitialClassificationOfCommonStockSubjectToPossibleRedemption", "terseLabel": "Change in value of common stock subject to possible redemption" } } }, "localname": "InitialClassificationOfCommonStockSubjectToPossibleRedemption", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "vhaq_InitialPublicOfferingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Initial Public Offering [Abstract]" } } }, "localname": "InitialPublicOfferingAbstract", "nsuri": "http://www.viveohealth.com/20210630", "xbrltype": "stringItemType" }, "vhaq_InitialPublicOfferingDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Initial Public Offering (Details) [Line Items]" } } }, "localname": "InitialPublicOfferingDetailsLineItems", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/InitialPublicOfferingDetails" ], "xbrltype": "stringItemType" }, "vhaq_InitialPublicOfferingDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Initial Public Offering (Details) [Table]" } } }, "localname": "InitialPublicOfferingDetailsTable", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/InitialPublicOfferingDetails" ], "xbrltype": "stringItemType" }, "vhaq_InitialPublicOfferingTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of initial public offering.", "label": "InitialPublicOfferingTextBlock", "terseLabel": "Initial Public Offering" } } }, "localname": "InitialPublicOfferingTextBlock", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/InitialPublicOffering" ], "xbrltype": "textBlockItemType" }, "vhaq_InterestAvailableToBeWithdrawnForPaymentOfTaxes": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest available to be withdrawn for payment of taxes.", "label": "InterestAvailableToBeWithdrawnForPaymentOfTaxes", "terseLabel": "Less: interest available to be withdrawn for payment of taxes" } } }, "localname": "InterestAvailableToBeWithdrawnForPaymentOfTaxes", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/ScheduleofnetlosspercommonsharebasicanddilutedforredeemableandnonredeemablecommonstockTable" ], "xbrltype": "monetaryItemType" }, "vhaq_InterestEarnedOnCashHeldInTrustAccount": { "auth_ref": [], "calculation": { "http://www.viveohealth.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest earned on cash held in trust account.", "label": "InterestEarnedOnCashHeldInTrustAccount", "negatedLabel": "Interest earned on investments held in Trust Account" } } }, "localname": "InterestEarnedOnCashHeldInTrustAccount", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "vhaq_MaturityTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maturity term.", "label": "MaturityTerm", "terseLabel": "Maturity term" } } }, "localname": "MaturityTerm", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/OrganizationandBusinessOperationDetails" ], "xbrltype": "durationItemType" }, "vhaq_MutualFundsHeldInTrustAccountMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MutualFundsHeldInTrustAccountMember", "terseLabel": "Mutual Funds held in Trust Account [Member]" } } }, "localname": "MutualFundsHeldInTrustAccountMember", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/ScheduleofassetsandliabilitiesthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "domainItemType" }, "vhaq_NonRedeemableCommonStockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NonRedeemableCommonStockAbstract", "terseLabel": "Non-Redeemable Common Stock" } } }, "localname": "NonRedeemableCommonStockAbstract", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/ScheduleofnetlosspercommonsharebasicanddilutedforredeemableandnonredeemablecommonstockTable" ], "xbrltype": "stringItemType" }, "vhaq_NumberOfWarrantsPurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants purchased.", "label": "NumberOfWarrantsPurchased", "terseLabel": "Number of warrants purchased (in Shares)" } } }, "localname": "NumberOfWarrantsPurchased", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/PrivatePlacementDetails" ], "xbrltype": "sharesItemType" }, "vhaq_NumeratorNetIncomeAllocableToCommonStockSubjectToPossibleRedemptionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NumeratorNetIncomeAllocableToCommonStockSubjectToPossibleRedemptionAbstract", "terseLabel": "Numerator: Net income allocable to common stock subject to possible redemption" } } }, "localname": "NumeratorNetIncomeAllocableToCommonStockSubjectToPossibleRedemptionAbstract", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/ScheduleofnetlosspercommonsharebasicanddilutedforredeemableandnonredeemablecommonstockTable" ], "xbrltype": "stringItemType" }, "vhaq_NumeratorNetLossIncomeMinusRedeemableNetEarningsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NumeratorNetLossIncomeMinusRedeemableNetEarningsAbstract", "terseLabel": "Numerator: Net (Loss) Income minus Redeemable Net Earnings" } } }, "localname": "NumeratorNetLossIncomeMinusRedeemableNetEarningsAbstract", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/ScheduleofnetlosspercommonsharebasicanddilutedforredeemableandnonredeemablecommonstockTable" ], "xbrltype": "stringItemType" }, "vhaq_OrganizationandBusinessOperationDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Business Operation (Details) [Line Items]" } } }, "localname": "OrganizationandBusinessOperationDetailsLineItems", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/OrganizationandBusinessOperationDetails" ], "xbrltype": "stringItemType" }, "vhaq_OrganizationandBusinessOperationDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Business Operation (Details) [Table]" } } }, "localname": "OrganizationandBusinessOperationDetailsTable", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/OrganizationandBusinessOperationDetails" ], "xbrltype": "stringItemType" }, "vhaq_OutstandingPublicSharesPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding public shares percentage.", "label": "OutstandingPublicSharesPercentage", "terseLabel": "Outstanding public shares percentage" } } }, "localname": "OutstandingPublicSharesPercentage", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/OrganizationandBusinessOperationDetails" ], "xbrltype": "percentItemType" }, "vhaq_PaymentForOfficeSpace": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount paid for office space.", "label": "PaymentForOfficeSpace", "terseLabel": "Payment for office space (in Dollars)" } } }, "localname": "PaymentForOfficeSpace", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "vhaq_PercentageOfOutstandingVotingSecurities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of outstanding voting securities.", "label": "PercentageOfOutstandingVotingSecurities", "terseLabel": "Percentage of outstanding voting securities" } } }, "localname": "PercentageOfOutstandingVotingSecurities", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/OrganizationandBusinessOperationDetails" ], "xbrltype": "percentItemType" }, "vhaq_PercentageOfRedemptionOfCompanysOutstandingPublicShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to percentage of trust account required for business combination.", "label": "PercentageOfRedemptionOfCompanysOutstandingPublicShares", "terseLabel": "Redemption percentage of outstanding public shares" } } }, "localname": "PercentageOfRedemptionOfCompanysOutstandingPublicShares", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/OrganizationandBusinessOperationDetails" ], "xbrltype": "percentItemType" }, "vhaq_PrivatePlacementDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Private Placement (Details) [Line Items]" } } }, "localname": "PrivatePlacementDetailsLineItems", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/PrivatePlacementDetails" ], "xbrltype": "stringItemType" }, "vhaq_PrivatePlacementDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Private Placement (Details) [Table]" } } }, "localname": "PrivatePlacementDetailsTable", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/PrivatePlacementDetails" ], "xbrltype": "stringItemType" }, "vhaq_PrivatePlacementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Private Placement Disclosure [Abstract]" } } }, "localname": "PrivatePlacementDisclosureAbstract", "nsuri": "http://www.viveohealth.com/20210630", "xbrltype": "stringItemType" }, "vhaq_PrivatePlacementDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of private placement.", "label": "PrivatePlacementDisclosureTextBlock", "terseLabel": "Private Placement" } } }, "localname": "PrivatePlacementDisclosureTextBlock", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/PrivatePlacement" ], "xbrltype": "textBlockItemType" }, "vhaq_PrivatePlacementWarrantsLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PrivatePlacementWarrantsLiabilityMember", "terseLabel": "Private Placement Warrants Liability [Member]" } } }, "localname": "PrivatePlacementWarrantsLiabilityMember", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/ScheduleofassetsandliabilitiesthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "domainItemType" }, "vhaq_ReconciliationOfNetIncomePerCommonSharePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ReconciliationOfNetIncomePerCommonSharePolicyTextBlock", "terseLabel": "Reconciliation of Net Income per Common Share" } } }, "localname": "ReconciliationOfNetIncomePerCommonSharePolicyTextBlock", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "vhaq_RedemptionOfPublicSharesPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redemption of public shares percentage.", "label": "RedemptionOfPublicSharesPercentage", "terseLabel": "Redemption of public shares percentage" } } }, "localname": "RedemptionOfPublicSharesPercentage", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/OrganizationandBusinessOperationDetails" ], "xbrltype": "percentItemType" }, "vhaq_RelatedPartyTransactionsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Line Items]" } } }, "localname": "RelatedPartyTransactionsDetailsLineItems", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "vhaq_RelatedPartyTransactionsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Table]" } } }, "localname": "RelatedPartyTransactionsDetailsTable", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "vhaq_ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of assets and liabilities that are measured at fair value on a recurring basis [Abstract]" } } }, "localname": "ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisAbstract", "nsuri": "http://www.viveohealth.com/20210630", "xbrltype": "stringItemType" }, "vhaq_ScheduleOfChangeInFairValueOfPrivatePlacementWarrantLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of change in fair value of private placement warrant liabilities [Abstract]" } } }, "localname": "ScheduleOfChangeInFairValueOfPrivatePlacementWarrantLiabilitiesAbstract", "nsuri": "http://www.viveohealth.com/20210630", "xbrltype": "stringItemType" }, "vhaq_ScheduleOfKeyInputsIntoTheMonteCarloSimulationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of key inputs into the Monte Carlo simulation [Abstract]" } } }, "localname": "ScheduleOfKeyInputsIntoTheMonteCarloSimulationAbstract", "nsuri": "http://www.viveohealth.com/20210630", "xbrltype": "stringItemType" }, "vhaq_ScheduleOfNetLossPerCommonShareBasicAndDilutedForRedeemableAndNonRedeemableCommonStockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of net loss per common share, basic and diluted, for redeemable and non-redeemable common stock [Abstract]" } } }, "localname": "ScheduleOfNetLossPerCommonShareBasicAndDilutedForRedeemableAndNonRedeemableCommonStockAbstract", "nsuri": "http://www.viveohealth.com/20210630", "xbrltype": "stringItemType" }, "vhaq_ShareOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares outstanding.", "label": "ShareOutstanding", "terseLabel": "Shares outstanding" } } }, "localname": "ShareOutstanding", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "vhaq_SharePerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share per Unit", "label": "SharePerUnit", "terseLabel": "Share Price (in Dollars per share)" } } }, "localname": "SharePerUnit", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/InitialPublicOfferingDetails" ], "xbrltype": "perShareItemType" }, "vhaq_SharesCancellationCommonStockSubjectToForfeiture": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares cancellation common stock subject to forfeiture.", "label": "SharesCancellationCommonStockSubjectToForfeiture", "terseLabel": "Shares cancellation common stock subject to forfeiture" } } }, "localname": "SharesCancellationCommonStockSubjectToForfeiture", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "vhaq_SharesOfCommonStockSubjectToPossibleRedemption": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares of common stock subject to possible redemption.", "label": "SharesOfCommonStockSubjectToPossibleRedemption", "terseLabel": "Shares of common stock subject to possible redemption (in Shares)" } } }, "localname": "SharesOfCommonStockSubjectToPossibleRedemption", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "vhaq_SharesSubjectToForfeiture": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares subject to forfeiture.", "label": "SharesSubjectToForfeiture", "terseLabel": "Shares subject to forfeiture" } } }, "localname": "SharesSubjectToForfeiture", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "vhaq_SponsorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SponsorMember", "terseLabel": "Sponsor [Member]" } } }, "localname": "SponsorMember", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "vhaq_StockPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock price.", "label": "StockPrice", "terseLabel": "Stock price (in Dollars per share)" } } }, "localname": "StockPrice", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/ScheduleofkeyinputsintotheMonteCarlosimulationTable" ], "xbrltype": "perShareItemType" }, "vhaq_UnderwritingFeeDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UnderwritingFeeDescription", "terseLabel": "Underwriting fee description" } } }, "localname": "UnderwritingFeeDescription", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "vhaq_ValueOfTrustAccount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "ValueOfTrustAccount", "terseLabel": "Value of trust account (in Dollars)" } } }, "localname": "ValueOfTrustAccount", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/OrganizationandBusinessOperationDetails" ], "xbrltype": "monetaryItemType" }, "vhaq_WarrantsExercisableToPurchaseSharesOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants exercisable to purchase shares of common stock.", "label": "WarrantsExercisableToPurchaseSharesOfCommonStock", "terseLabel": "Warrants exercisable to purchase shares of common stock (in Shares)" } } }, "localname": "WarrantsExercisableToPurchaseSharesOfCommonStock", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "vhaq_WarrantsRedemptionDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants redemption, description.", "label": "WarrantsRedemptionDescription", "terseLabel": "Warrants redemption, description" } } }, "localname": "WarrantsRedemptionDescription", "nsuri": "http://www.viveohealth.com/20210630", "presentation": [ "http://www.viveohealth.com/role/WarrantsDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r105": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r107": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(3)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r142": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569655-111683" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r187": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r211": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r216": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.23)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r255": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r256": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r257": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r258": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r259": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r260": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r261": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.19)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(b))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r55": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r85": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" } }, "version": "2.1" } ZIP 48 0001213900-21-042941-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-21-042941-xbrl.zip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end